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1. Introduction 
1.1 Objective of the study 
Globally, there are 270,000 new cases of kidney cancer diagnosed yearly 
and approximately 90% of all kidney cancers are clear cell renal cell 
carcinoma (RCC). About 20-30% of all patients have metastatic disease at 
time of diagnosis, and another 20% of patients undergoing nephrectomy 
will develop metastases during follow-up (Ljungberg, Campbell et al. 
2011). Therefore, it is of vital importance to find effective prognostic 
markers and new therapeutic targets to enable risk stratification and 
individualized therapeutic strategy in RCC patients.  
The objective of this study was the identification of novel independent 
prognostic markers and potential therapeutic targets in clear cell RCC, 
based on a biobank with patients’ tissue samples, histopathological 
information and the corresponding follow-up data. Various approaches 
were used for selection of promising candidate genes: Epithelial-
mesenchymal transition (EMT) is an established theory for interpretation 
of tumor invasion and tumor metastasis in solid tumors. Since there is 
almost no data available about the role of EMT in RCC and about its 
potential impact on the outcome, EMT-related genes were in the focus of 
this study. Additionally, genes related to cancer stem cells, organ size 
controlling Hippo pathway, and CXCR4 signaling pathway were analyzed 
in this study. Details of EMT and the other investigated pathways are 
provided in the following sections. 
1.2 Epithelial-mesenchymal transition  
Carcinoma cells undergo a characteristic change from an epithelial to a 
mesenchymal cell-like phenotype called epithelial-mesenchymal transition 
(EMT) during cancer progression (Figure 1) (Polyak and Weinberg 2009, 
Thiery, Acloque et al. 2009, Tiwari, Gheldof et al. 2012). This kind of cell 
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phenotype change can facilitate tumor cell migration and invasion at an 
early stage of tumor development and form distant metastasis (Rhim, 
Mirek et al. 2012). Increasing evidence supports the notion that the 
dynamic process of EMT gives rise to tumor cell dissemination and, 
together with mesenchymal-epithelial transition (MET), the reversal of 
EMT, finally leads to outgrowth of metastases (Brabletz 2012, Tsai, 
Donaher et al. 2012). More recently, it has been shown that the 
mesenchymal properties gained during EMT are shared by cancer stem 
cells (Mani, Guo et al. 2008). This is clinically highly relevant since cancer 
stem cells are thought to selectively survive chemotherapy due to their 
insensitivity to drugs which can lead to disease relapse (Singh and 
Settleman 2010). In addition, EMT genes attract interest for their clinical 
significance as prognosis predictors or potential therapeutic targets 
(Iwatsuki, Mimori et al. 2010, Singh and Settleman 2010). Based on the 
EMT theory, mesenchymal cell markers such as vimentin and fibronectin 
1 should be up-regulated during the process of tumorigenesis, while the 
epithelial cell markers, such as E-cadherin, will lose the expression 
density. This process was recognized as a loss of cell polarity, stability and 
gain of migration and invasion ability in cancer cells. EMT is mostly under 
transcriptional control. Important players of EMT are master 
transcription factors like ZEB and SNAIL family members which can 
induce EMT upon overexpression (De Craene and Berx 2013). Loss of cell 
adhesion molecule E-cadherin expression mediated by transcriptional 
repression of CDH1 (encoding E-cadherin) through ZEB and SNAIL 
transcription factors and induction of extracellular matrix-degrading 
metalloproteinase (MMPs), such as MMP2 and MMP9, are hallmarks of 
EMT that facilitate the invasive phenotype (De Craene and Berx 2013). 
The EMT process can be induced by cytokines and growth factors such as 
transforming growth factor β (TGF-β) which are produced by the tumor 
stroma or possibly by the tumor cells (Heldin, Vanlandewijck et al. 2012). 
INTRODUCTION 
3 
 
It is widely accepted that EMT plays an important role in a number of 
solid tumors (Thiery, Acloque et al. 2009, Iwatsuki, Mimori et al. 2010). 
 
Figure 1: Overview of Epithelial-mesenchymal transition: (A) simplified 
overview of signaling networks regulating epithelial–mesenchymal transition 
(EMT). (B) Transitions between epithelial and mesenchymal states during 
carcinoma progression. In the primary tumor, EMT and mesenchymal-epithelial-
transition (MET) contribute to intratumoral heterogeneity. Interactions with 
stromal cells, including leukocytes and cancer-associated fibroblasts (CAFs), may 
induce EMT. Macroscopic distant metastases are frequently composed of more 
differentiated epithelial cancer cells. This may be explained by MET, a reversal 
of EMT, after macrometastases grow. Functional cooperation of cancer stem cells 
and epithelial cancer cells are not well established. (Polyak and Weinberg 2009) 
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1.3 Molecular links between cancer stem cells and epithelial-
mesenchymal transition during metastasis 
From a biological point of view metastasis in various solid tumors is 
comprised by several distinct steps named “invasion-metastasis cascade”. 
This cascade includes gain of traits like invasiveness leading to 
immigration into surrounding tissues and lymphatic and blood vessels 
(intravasation), exit from vasculature (extravasation), and finally 
enhanced survival and proliferation in the foreign environment to form 
metastases (colonization) (Aktas, Tewes et al. 2009, Geiger and Peeper 
2009). 
In the early stage of metastasis, primary tumor cells need to invade and 
disseminate from the primary tumor which needs coordination of 
transcription factors such as TWIST, SNAIL, SLUG, and ZEB1 to repress 
expression of epithelial adhesion molecules such as E-cadherin. At the 
same time, mesenchymal components such as N-cadherin, vimentin and 
fibronectin are up-regulated. After intravasation and extravasation, 
cancer cells need to adapt to the colony environment and grow as 
metastasis. In this stage, stem cell properties of self-renewal, tumor-
initiating and high proliferation capacity are taking place.  
Taken together, cells which successfully escape from the primary tumor 
and colonize distant organs are supposed to undergo an EMT process in an 
early stage to gain mesenchymal traits and also gain cancer stem cell 
properties to finally leading to clinical progression. 
Many details of the biological process of metastasis in RCC are still 
unclear. Identification of biomarkers which can be used as independent 
prognostic predictors or therapeutic targets is crucial for RCC patients. 
For basic research, it is also important to investigate promising genes 
involved in RCC metastasis and to clarify the mechanism of tumor 
metastasis. Since no clear boundary between EMT and stem cell 
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properties can be defined and many genes were reported to be involved in 
both, genes which are related to these two processes were selected as 
promising targets in this study. 
Given the essential role of EMT for tumor progression in other carcinomas 
and the limited information available for RCC, we decided to 
comprehensively analyze EMT-associated gene expression in RCC. 
Because EMT is a transcriptionally regulated differentiation process, we 
used transcriptome analysis and RT-PCR to quantify EMT-related gene 
expression. We assembled a list of 46 genes which were reported in 
literature to be up-regulated during EMT in different epithelial cancers.  
1.4 Trophoblast glycoprotein (TPBG), CXCR4 and EMT 
Functional interaction of TPBG (previously known as 5T4) and the tumor 
stem cell marker CXCR4 has been reported previously. However, the 
mechanisms behind are still not completely resolved. Since TPBG shows 
high expression in malignant tissues and promising results as a 
therapeutic target (Shaw, Connolly et al. 2007, Elkord, Shablak et al. 2009, 
Tykodi, Satoh et al. 2012), it was selected as a candidate in this study too. 
CXCR4 has been recognized as a tumor stem cell marker in various 
epithelial tumors, and interaction between CXCR4 and EMT has been 
reported (Onoue, Uchida et al. 2006, Li, Ma et al. 2012, Gassenmaier, 
Chen et al. 2013). Therefore, it was also selected for analysis in this study. 
1.5 Another investigation approach: identification of progression 
related genes by microarray data analysis 
Additionally to the focus on EMT-related genes including TPBG and 
CXCR4, a second strategy was used in this study to identify new 
prognostic markers in RCC: microarray expression data from RCC 
patients including normal kidney tissues from tumor-bearing kidney, 
primary tumors and metastases were analyzed to screen for promising 
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prognostic markers using a novel filtering approach, based on genes that 
are subsequently up-regulated in primary tumors and metastases.  
In this approach, the hypothesis is as follows: in the tumor progression 
sequence “normal kidney tissue – primary tumor – metastases”, genes 
that show increasing expression in a progression-dependent way could be 
especially important for RCC biology and therefore interesting for further 
research.  
In principle, these genes can encode either harmful or protective factors 
during tumor progression. Regardless of the biological role of these 
molecules, they might also be interesting for this study by coding for 
prognostic factors in RCC patients. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
HEK-293T cells (human embryonic kidney) were used for as control in 
transfection experiments. RCC cell lines RCC53 (Djafarzadeh, Noessner et 
al. 2006) and SK-RC-17 (Ebert, Bander et al. 1990) were kindly provided 
by PD Dr. Heike Pohla, Tumor Immunology Laboratory, LIFE Center, 
LMU, München. 
2.1.2 Patient tissues  
Tissue samples from primary tumors and metastases were collected from 
clear cell renal cell carcinoma (RCC) patients undergoing surgical 
resection of RCC at two different centers. A total of 42 samples including 
14 normal tissues from tumor-bearing kidneys, 28 primary tumors (14 
grade G1 and G3 tumors each) were used for microarray analysis 
(Department of Urology, University of Rostock). The characteristics of this 
microarray patient cohort are summarized in Table 1. Another 112 tissue 
samples from 82 patients with clear cell RCC were used for real-time PCR 
analyses, including 19 normal tissues from tumor-bearing kidneys, 55 
primary tumors and 38 metastases from various locations which were 
used for survival analysis. 32 metastases (those with the best RNA quality) 
were also used for microarray analysis with the normal-primary-
metastases comparison approach. From each patient and site, one tissue 
sample was analyzed. The patients underwent tumor nephrectomy, partial 
nephrectomy or resection of metastases between 1992 and 2011 at the 
Department of Urology, University of Munich. The characteristics of these 
patients are summarized in Table 2. The median follow-up time was 54 
months. Staging was performed according to the Ficarra TNM 
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classification (Sobin L 2009). Normal tissue samples were taken from 
tumor-bearing kidneys and approved by a pathologist to be histologically 
normal. All patients gave informed consent, and the research was 
approved by the local ethics committees.  
Table 1: Patient characteristics: Cohort of Rostock (Maruschke, Hakenberg et al. 
2013) 
 Primary G1 n (%) Primary G3 n (%) 
Total no. patients 14 14 
 
Age (years)   
 Median (range) 65 (53–77) 59 (48–79) 
 
Sex (%)   
 Male 8 (57) 9 (64) 
 Female 6 (43) 5 (36) 
 
Pathological stage (%)   
 pT1–2 13 (93) 3 (21) 
 pT3a 1 (7) 3 (21) 
 pT3b 0 (0) 8 (58) 
 pT4 0 (0) 0 (0) 
 
Pathological nodal 
status (%) 
  
 Negative 14 (100) 10 (71) 
 Positive 0 (0) 3 (21) 
 Unknown (pNX) 0 (0) 1 (8) 
 
Distant metastases (%)   
 M0 14 (100) 3 (21) 
 M1 0 (0) 11 (79) 
 
Tumor grade (%)   
 G1 14 (100) 0 (0) 
 G2 0 (0) 0 (0) 
 G3 0 (0) 14 (100) 
 
Normal renal tissue 
available (%) 
8 (57) 6 (43) 
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Table 2: Patient characteristics of RT-PCR: Cohort of Munich 
 Classification Primary tumors: n (%) Metastases: n (%) 
T  
T1-T2 
 
29 (52.7) 
 
12 (31.6) 
 T3-T4 26 (47.3) 26 (68.4) 
N  
N0 
 
41 (74.5) 
 
22 (57.9) 
 N+ 10 (18.2) 11 (28.9) 
 NX 4 (7.3) 5 (13.2) 
M  
M0 
 
26 (47.3) 
 
16(42.1) 
 M1 29 (52.7) 22 (57.9) 
G  
G1-G2 
 
45 (81.8) 
 
22 (57.9) 
 G3 10 (18.2) 16 (42.1) 
Age  
<60 
 
22 (40.0) 
 
23 (60.5) 
 ≥60 33 (60.0) 15 (39.5) 
Gender  
Male 
 
32 (58.2) 
 
23 (60.5) 
 Female 23 (41.8) 15 (39.5) 
Metastatic 
Site (%) 
 
Adrenal gland 
 
 
 
12 (31.6) 
 Lymph node  12 (31.6) 
 Lung  7 (18.4) 
 Liver  4 (10.5) 
 Cava  2 (5.3) 
 Brain  1 (2.6) 
 
2.1.3 Primers 
All primers were designed using the online tool primer-blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Ye, Coulouris et al. 
2012). Primers were supplied by Eurofins (Ebersberg, Germany); 
sequences and product sizes are listed in Table 3. Quality control was 
performed for all primers. Primers were only used for RT-PCR when the 
melting curve of the amplified products had only one peak, and when only 
one clear band of product with the expected size was detected by agarose 
gel electrophoresis. 
Table 3: Oligonucleotides used for RT-PCR 
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Primer ID Sequence (5'→3'): 
Product 
size (bp) 
AMPD3_f TTGCAGAGACAGGGACTGG 116 
AMPD3_r AAAAGGAAGCCAAGGAGAGG  
ATAD2_f TCCGGTGGTAGGTTTCAACT 130 
ATAD2_r TTCCTCAGTCTGGAGCACATC  
AURKA_f GCTGGAGAGCTTAAAATTGCAG 141 
AURKA_r TTTTGTAGGTCTCTTGGTATGTG  
BUB1B_f CCAGGCTTTCTGGTGCTTAG 148 
BUB1B_r CTCGTGGCAATACAGCTTCA  
CDH1_f GAATGACAACAAGCCCGAAT 88 
CDH1_r GACCTCCATCACAGAGGTTCC  
CDH2_f GGTGGAGGAGAAGAAGACCAG 71 
CDH2_r GCATCAGGCTCCACAGT  
CDT2/DTL_f CCATATCCCTGAGGACTGTGT 282 
CDT2/DTL_r TTCCCAAAGCCCAACAGTCA  
CENPF_f TTGTAAAGAAAGGGTTTGC 172 
CENPF_r CCAGCTGTTGGTTTGGAGG  
CXCL12_f ACTGGGTTTGTGATTGCCTCTGAA 150 
CXCL12_r GGAACCTGAACCCCTGCTGTG  
CXCR4_f TGGGTGGTTGTGTTCCAGTTT 80 
CXCR4_r ATGCAATAGCAGGACAGGATGA  
CXCR7_f TACCCCGAGCACAGCATCAA 82 
CXCR7_r TGGAGAAGGGAACGGCAAAG  
FN1_f AAACCAATTCTTGGAGCAGG 142 
FN1_r CCATAAAGGGCAACCAAGAG  
GAPDH_f CAACTACATGGTTTACATGTTC 180 
GAPDH_r GCCAGTGGACTCCACGAC  
HELLS_f CCCTCCTTTCTTCTAGTAATGCAGTT 81 
HELLS_r CCCAATCTCTCCCCATGAAAA  
MMP2_f TTGATGGCATCGCTCAGATC 82 
MMP2_r TTGTCACGTGGCGTCACAGT  
MMP9_f GCAAGCTGGACTCGGTCTTT 64 
MMP9_r TGGCGCCCAGAGAAGAAG  
NDC80_f AGGACCTGGAAGCTGAACAA 75 
NDC80_r TTTCAATCGCTTCTTTGCCT  
S100A4_f GGCTTGCACACGCTGTTGCT 71 
S100A4_r GCCTTCTCCAGAGGGCACGC  
SFN_f GAGGAAACATGGTCACACCC 134 
SFN_r TGAGAACTGGACAGTGGCAG  
MATERIALS AND METHODS 
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SLUG_f TGTTGCAGTGAGGGCAAGAA 72 
SLUG_r GACCCTGGTTGCTTCAAGGA  
SYBU/GOLSYN_f TTCTTCACGCAATCGAGGTCC 207 
SYBU/GOLSYN_r GGGCTACAGTCGCTTCCTTT  
TET3_f TCCAGCAACTCCTAGAACTGAG 169 
TET3_r AGGCCGCTTGAATACTGACTG  
TOP2A_f CATTGAAGACGCTTCGTTATGG 104 
TOP2A_r CCAGTTGTGATGGATAAAATTAATCAG  
Twist_f TGTCCGCGTCCCACTAGC 93 
Twist_r TGTCCATTTTCTCCTTCTCTGGA  
VIM_f AAAGTGTGGCTGCCAAGAAC 74 
VIM_r AGCCTCAGAGAGGTCAGCAA  
ZEB1_f GCCAATAAGCAAACGATTCTG 101 
ZEB1_r TTTGGCTGGATCACTTTCAAG  
ZEB2_f GCGGCATATGGTGACACACAA 81 
ZEB2_r CATTTGAACTTGCGATTACCTGC  
 
2.1.4 Antibodies, plasmids, chemicals, bacteria and antibiotics 
All reagents and bacteria used in the study are listed in Table 4. 
Table 4: Materials used in this study 
 Catalog No. Company 
Antibodies: 
 
  
Anti-CXCR4 monoclonal rabbit 
antibody, clone UMB2 
ab124824 Abcam plc. 
Anti-human CXCR4 Antibody 
monoclonal mouse antibody (IgG2B), 
Clone 44716 
MAB172 R&D Systems 
Anti-CXCR4 polyclonal rabbit antibody Ab2074 Abcam plc. 
Anti-human CXCR4 polyclonal rabbit 
antibody 
19490002 Novus 
Biologicals. 
Anti-MMP2 monoclonal mouse antibody 
(IgG1), clone 4D3 
ab2462 Abcam plc. 
Anti-human 5T4 monoclonal mouse 
antibody (IgG1), Clone 524731 
MAB4975 R&D Systems 
Anti-mouse CD184/CXCR4 PE 
monoclonal rat antibody (IgG2b) 
12-9991-81 eBioscience 
Anti-human 5T4-APC monoclonal 
mouse antibody (IgG1), clone 524744 
FAB49751A R&D Systems 
Anti-topoisomerase II alpha monoclonal 
rabbit antibody (IgG), clone EP1102Y 
ab52934 Abcam plc. 
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Anti-TET3 polyclonal rabbit antibody PA5-34431 Thermo Fisher 
Scientific Inc. 
Anti-human Ki-67 monoclonal mouse 
antibody, clone MIB-1 
M7240 Dako 
Anti-Lsh mouse monoclonal antibody 
(IgG2a), clone H-4 
sc-46665 Santa Cruz 
Biotechnology 
Anti-ZEB1 monoclonal mouse antibody 
(IgG2a), clone 4C4 
H00006935-M01 Abnova 
Corporation. 
Anti-β-actin monoclonal mouse antibody 
(IgG2a), clone AC-74 
A5316 Sigma-Aldrich 
Co. 
Anti-mouse IgG (H and L Chain) 
polyclonal goat antibody, peroxidase- 
conjugated 
401215 Calbiochem 
Anti-mouse IgG polyclonal goat 
antibody (H and L chain), Alexa Fluor® 
633-conjugated 
A21050 Life 
Technologies 
Other compounds: 
 
  
AMD3100 octahydrochloride 3299 TOCRIS 
bioscience 
Recombinant CXCL12/SDF-1a, CF 
 
350-NS/CF R&D Systems 
Transfection materials: 
 
  
pCMV6-XL5-human TPBG 
contains Homo sapiens trophoblast 
glycoprotein , transcript variant 1 as 
transfection-ready DNA 
SC115948 OriGene 
Technologies 
pCMV-SPORT6-human CXCR4 IRAVp968H08146D Source 
BioScience  
Fusin siRNA, 10 mM sc-35421 Santa Cruz 
Control siRNA-A; 10 mM sc-37007 Santa Cruz 
siRNA Transfection Reagent, 0.3 ml sc-29528 Santa Cruz 
siRNA Transfection Medium, 20 ml sc-36868 Santa Cruz 
siRNA Dilution Buffer, 1.5 ml sc-29527 Santa Cruz 
FuGENE® 6 Transfection Reagent 11815091001 Roche 
X-tremeGENE HP DNA Transfection 
Reagent 
06 366 244 001 Roche 
QIAquick PCR Purification Kit 28104 QIAGEN 
QIAprep Spin Miniprep Kit 27104 QIAGEN 
NucleoBond® Xtra Maxi Plus 
 
740416.10 MACHEREY-
NAGEL GmbH 
Cell biology experiments materials: 
 
  
RPMI 1640 21875-034 Gibco 
PBS, sterile  10010-015(056) Gibco 
Accutase L11-007 PAA 
Inserts for 24-well plates 353097 BD Biosciences 
BD Matrigel™ Basement Membrane 354262 BD Biosciences 
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Matrix High Concentration, Phenol Red 
Free, 10 ml vial 
L-Glutamine 200mM(100x), 100 ml 25030-024 Life 
Technologies 
MEM Non-Essential Amino 
Acids(100x), 100 ml 
11140-035 Life 
Technologies 
Sodium Pyruvate MEM 100 mM, 100 ml 11360-039 Life 
Technologies 
Acetone ACS grade, 2.5 liter 1.00014.2500 Merck 
Methanol ACS grade, 2.5 liter 106009.2500 Merck 
CellTiter-Blue® Cell Viability Assay G8081 Promega 
Corporation.  
µ-Dish 35 mm, high Culture-Insert 81176 ibidi 
7-Amino-actinomycin D (7-AAD) 
staining solution 
559925 BD Biosciences 
HEPES, 1M, 20 ml 15630-049 Gibco 
EDTA, 0.5M, 100 ml AM9260G Ambion 
Ultra-Low Attachment flask: 25/75 cm² 3471 Corning 
DMEM/F12 1221806 Gibco 
Insulin-transferrin-selenium-x (ITS-x), 
100x 
51500-056 Gibco 
B 27 17504-044 Invitrogen 
Basic fibroblast growth factor (bFGF) F0291 Sigma 
Epithelial growth factor (EGF) 
 
PHG0311 Life 
Technologies 
 
Immunochemistry materials: 
 
  
Hematoxylin Solution HHS16-500ML Sigma 
ImmPRESS Universal Antibody (anti-
mouse Ig/anti-rabbit Ig, peroxidase) 
Polymer Detection Kit  
MP-7500 Vector 
Laboratories 
ImmPACT AEC Peroxidase Substrate SK-4205  Vector 
Laboratories 
BLOXALL Endogenous Peroxidase and 
Alkaline Phosphatase Blocking Solution 
 
SP-6000  Vector 
Laboratories 
Western blotting (WB) materials: 
 
  
Coomassie (Bradford) protein Assay Kit 23200 Thermo Fisher 
Scientific Inc. 
SuperSignal® West Pico 
Chemiluminescent Substrate 
34079 Thermo Fisher 
Scientific Inc. 
NuPAGE® Bis-Tris Mini Gels IM-8042 Life 
Technologies 
Corporation 
NuPAGE® Transfer Buffer(20x) NP0006 Life 
Technologies  
NuPAGE® RunningBuffer(20x) NP0001 Life 
Technologies  
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Precision Plus Protein Dual Color 
Standards, 500 µl 
161-0374 Bio-Rad 
GE Healthcare AmershamHyperfilm 
ECL 
28906837 Amersham 
DL-Dithiothreitol (DTT), 1 g 
 
D9163 Sigma-Aldrich, 
Inc. 
Real-time PCR materials:   
RNeasy Mini Kit 74104 QIAGEN 
LightCycler® FastStart DNA Master 
plus SYBR Green I Kit 
03515885001 Roche 
Reverse Transcription System A3500 Promega 
Corporation. 
QIAshredder Kit 79654 QIAGEN 
RNA 6000 Pico Assay 50671513 Agilent 
Technologies 
Gene Ruler 100bp DNA ladder SM0241 Fermentas 
Gene Ruler 1kb DNA ladder SM0311 Fermentas 
6x DNA Loading Dye, 1 ml R0611 Fermentas 
99% Ethanol 100990 Merck 
ß-ME M3148 Sigma 
UltraPure™ Agorose, 500 g 16500500 Life 
Technologies  
UltraPure™ 10 x TAE buffer 15558042 Life 
Technologies  
Ethidium Bromide Solution,  
10 mg/ml 
161-0433 Bio-rad 
2.1.5 Buffers and solutions 
The following buffers and solutions were made for different experiments: 
Lysogeny broth (LB) media (a total of 1 liter) contains: 10 g Bacto-
Tryptone, 5 g Bacto-Yeast extracts and 5 g NaCl. The pH value is 7.5. 
Solution was sterilized by autoclaving and stored at room temperature. 
LB media (a total of 1 liter) contains: 15 g Bacto-Agar, autoclaved and 
stored at 4°C. 
Ampicillin: 100 mg/ml (stock solution, -20°C), 1:1000 diluted in agar to a 
concentration of 100 µg/ml. 
SOC Media contains: 800 ml deionized H2O, 20 g Bacto-Tryptone, 5 g 
Bacto-Yeast Extract and 0.5 g NaCl. 
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10x PBS / for Western blotting contains (a total of 1 liter): 80 g/l NaCl,      
2 g/l KCL, 11.5 g/l Na2HPO4 or 14.8 g/l Na2HPO4-(H2O) 2, 2 g/l KH2PO4 and 
adjusted to 1 liter with distilled water. 
Protein lysis buffer stock solution contains: 50 mM Tris-HCl (pH 8.0, 1 ml 
Tris-HCL plus 19 ml nuclease free water), 150 mM NaCl (8.77 g/l, 175.4 
mg for 20 ml), 1% Triton X-100 (200 µl for 20 ml) and “Complete Mini- 
Protease Inhibitor Cocktail”(1 tablet for 1.5 ml lysis buffer). 
Running buffer for WB contains: 10 ml 20x running buffer plus 190 ml 
dH2O. 
Transfer buffer for WB contains: 10 ml 20x buffer, 20 ml Methanol and 
170 ml H2O. 
Blocking milk buffer: 25 g (5%) skim milk powder + 50 mL 10x PBS + 500 
µl Tween 20 adjusted to 500 ml with dH2O. 
1x TBS contains: 50 mM Tris pH 8.0, 138 mM NaCl, 2.7 mM KCl. 
1x TBS-T (a total of a liter) contains: 1 liter 1x TBS, 500 µl Tween 20. 
Gel for DNA-fragment analysis: 2% agarose dissolved in 100 ml TBS 
buffer, cool down and add 1 µl ethidium bromide (EtBr; 10 mg/ml); pour in 
tray of electrophoresis apparatus for solidification. 
Cell culture standard media: RMPI 1640 media 500 ml, 50 ml FBS, 5 ml 
MEM, 5 ml sodium pyruvate and 5 ml L-glutamine. 
Sphere formation assay media: DMEM/F12 96.84%, ITS-X 1% (v/v), B27 2% 
(v/v), bFGF 0.08%, EGF 0.08%. 
FACS buffer (for 40 ml): 38.28 ml PBS, 1 ml of 1 M HEPES, 320 µl of 0.5 
M EDTA and 400 µl FBS. 
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2.1.6 Apparatus and software 
Apparatus and software used in the study are listed below: BZ-8000 
microscope (Keyence Corporation, Osaka, Japan); Light Cycler 96 (Roche, 
Penzberg, Germany); High-speed Centrifuge (Eppendorf, Hamburg, 
Germany), Bioanalyzer 2100 (Agilent, Böblingen, Germany); NanoDrop 
2000 (Thermo Fisher Scientific);  Peltier Thermal Cycler DNA Engine 
PTC-200 (Bio-Rad, Munich, Germany); Fluor-S™ MultiImager (Bio-Rad, 
Munich, Germany); Horizontal Gel Electrophoresis System (Gibco / Life 
Technologies, Darmstadt, Germany); Thermomixer comfort (Eppendorf, 
Hamburg, Germany); FACS Calibur™ (BD Bioscience, Heidelberg, 
Germany); Cell Quest Pro software (BD Bioscience, Heidelberg, Germany); 
FlowJo (Tree Star Inc., Ashland, OR, USA). 
 
2.2 Cell culture 
The human renal cell carcinoma cell lines RCC53 and SK-RC-17 and the 
human embryonal kidney cell line HEK-293T were obtained from the 
Tumor Immunology Laboratory, LIFE Center of Klinikum Großhadern. 
All cells were recovered from liquid nitrogen and maintained in RPMI 
1640 media (Invitrogen, Life Technologies GmbH, Darmstadt, Germany) 
supplemented with 10% FBS (Biochrom AG, Cambridge, UK), 1% MEM 
non-essential amino acids, 1 mM sodium pyruvate, and 2 mM L-glutamine 
(all from Invitrogen, Life Technologies GmbH, Darmstadt, Germany). 
Cells were cultured at 37°C in a humidified atmosphere containing 5% 
CO2 and passaged by Accutase (PAA Laboratories, Freiburg, Germany) 
detachment. Before detachment, cells were washed with water-bath (37°C) 
pre-warmed PBS (Invitrogen, Life Technologies GmbH, Darmstadt, 
Germany) to get rid of the culturing media. After incubation for 5 min in 1 
ml Accutase at 37°C, 10 ml (10-fold excess) of pre-warmed (37°C) complete 
culturing media was added to block the digestion process, and cells were 
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collected by centrifugation (1,200 rpm, 5 min). Cell pellets were then re-
suspended using complete media and transferred to new flasks. For 
freezing and thawing of cells, detached cells after Accutase digestion were 
centrifuged and re-suspended in 1ml freezing media (FBS supplemented 
with 10% DMSO) and transferred into a cryotube, then stored at -80°C for 
short term storage (1 month) or nitrogen tank for long term storage.  
 
2.3 Plasmid transformation, preparation, validation and 
transfection 
2.3.1 Plasmid DNA transformation 
Transformation of competent cells with plasmid DNA 
 Remove 20 or 25 µl bacteria aliquot from -80°C and let thaw on ice (it is 
important to keep competent cells cool). Give first of each ligation 
mixture 2 (2.5) µl to 20 (25) µl bacterial suspension, mix briefly in 2 ml 
Eppendorf tube, then incubate for 30 min on ice. 
 When plasmid was obtained on blotting paper, then dissolve the DNA 
in 30 µl of water (transfer paper into Eppendorf tube), leave for 10 min, 
then centrifuge for 1 min, remove paper. For transformation, use 
similar quantity as above. 
 For control (positive control), add 50 ng of vector in 1 µl to 25 µl 
bacteria aliquot. 
 Incubate for heat shock 45 s at 42°C, then immediately transfer to ice 
for 2 min (minimum time) followed by adding 125 µl of pre-warmed 
(42°C) SOC media (Invitrogen ). Then shake in a shaker at 37°C for 1 h 
at 650 rpm. 
 Spread on LB agar plates containing the appropriate antibiotic (e.g., 
100 g/ml ampicillin). Tip:  Spread by evenly spreading cells over the 
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plate using a “hockey puck” spreader. Be sure that you have dipped 
your spreader in ethanol and flamed it before spreading. 
 Place in the 37°C incubator with the lid side down. Incubate overnight 
then transfer to refrigerator (4°C) sometime the next day. 
2.3.2 Maxi preparation 
 Pick single clone and add it in 100 ml of LB media. 
 Incubate at 37°C, shaking (200 rpm) over night 
 Perform plasmid DNA purification using NucleoBondXtra, Maxi Plus 
according to the manufacturer’s instructions. 
2.3.3 Restriction endonuclease digestion and DNA purification 
For enzyme digestion, mix and spin down: 
35 µl nuclease free water 
5 µl 10x Fast Digest Buffer 
5 µl plasmid DNA 
5 µl NotI Fast Digest enzyme 
 
QIAquick PCR Purification Kit: 
 Add 5 volumes PB Binding Buffer to 1 volume of PCR sample: add   
250 µl PB Binding Buffer to 50 µl PCR sample 
 Transfer DNA binding column to 2 ml collection tube, fill with mixed 
sample, and centrifuge for 1 min at 13,000 rpm. 
 Discard flow-through and put column back into the same tube. 
 Add 750 µl PE buffer to the column for washing and centrifuge for 
another 1 min. 
 Discard flow-through and put column back into the same tube. 
37°C for 1 h, followed by 80°C, 
10 min to inactivate the enzyme 
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 Centrifuge the column again for 1 min to completely remove the 
residual alcohol containing PE buffer (might interfere with later use).  
 Transfer QIAquick column into a new 1.5 ml microcentrifuge tube 
(Eppendorf tube). 
 For the extraction of DNA, pipette 30 µl of EB buffer onto the center of 
the membrane, let stand for 1 min, then centrifuge for 1 min. 
 Discard column, store purified DNA at -20°C and check the length 
using gel of DNA fragment using gel electrophoresis. 
2.3.4 Transfection 
One day before transfection, cells were seeded in 6-well plates. Cells were 
cultured to 60-80% confluence. Plasmid DNA transfection solution was 
prepared as follows: 97 µl RPMI, 3 µl Fugene transfection reagent, 2 µl 
plasmid DNA per well of 6-well plate. Allow to stand for 30 min, and then 
fill up with 6 ml RPMI. Aspirate the old medium and fill each well with 1 
ml of transfection solution. Forty-eight h after transfection, cells can be 
analysed for protein expression by flow cytometry (see 2.4) or Wetern blot 
(see 2.7). 
 
2.4 Flow cytometry (FC) 
Flow cytometry was used to measure the cell membrane expression of 
TPBG and CXCR4. 
2.4.1 Cell preparation and flow cytometry 
 Harvest cells from 70-90% confluent cells in T75 flask 
 Spin cells down (1,200 rpm, 5 min) 
 Count cells 
 Re-suspend 5x105  cells in 100 µl FACS buffer 
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 Stain cells with 10 µl anti-CXCR4 (PE) or 10 µl anti-TPBG (APC) 
antibody for 30 min at room temperature in the dark (briefly vortex in 
between) 
 Wash cells with 600 µl FACS buffer 
 Centrifuge cells (1,500 rpm, 5 min) 
 Re-suspend cells in 100 µl FACS buffer 
 Add 5 µl 7-AAD (concentration as supplied) for live/dead discrimination 
 Store the cells for 10 min in the fridge in the dark until analysed 
2.4.2 Setup, data acquisition and analysis 
 Switch on FACS Calibur first and then computer 
 Start software: FACS Pro 
 Acquire-connect to cytometer 
 Acquire/parameter Description: P1 for FSC, P2 for SSC, P4 for PE 
staining, P5 for 7-ADD staining, and P7 for APC staining. 
 Set directory and file count 
 Adjust cytometer/instrument setting 
 For data acquisition, count more than 20,000 events 
 Data analysis is done using FlowJo software (Tree Star. Inc., Ashland, 
USA) 
 
2.5 Quantitative PCR 
2.5.1 RNA isolation and concentration measurement 
 Prepare: Buffer RLT containing ß-ME (add 10 µl ß-ME to 1 ml RLT); 
Buffer RPE(add 96-100% ethanol as required by the manufacturer); 70% 
ethanol 
 Tissue amount should be less than 30 mg. 
 Add 600 µl RLT buffer to tissue(storage up to 1 month at room 
temperature) 
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 Transfer to QIAshredder, centrifuge for 2 min, maximum speed, 
transfer supernatant to column 
 Add 600 µl 70% ethanol to supernatant and mix by pipetting (do not 
centrifuge) 
 Add 700 µl mixed sample to column inserted in a Eppendorf tube (2 ml), 
centrifuge for 15 s, maximum speed, discard the flow-through 
 Add 700 µl RW1 buffer to column, centrifuge for 15 s, maximum speed, 
discard the flow-through 
 Transfer the column in new collection tube (2 ml) 
 Add 500 µl RPE buffer, centrifuge for 15 s, maximum speed, discard 
the flow-through(centrifuge again for 2 min) 
 Transfer the column to a RNase-free tube (1.5 ml), add 50 µl of RNase-
free water to the membrane of the column, centrifuge for 1 min, 
maximum speed, collect the flow-through (repeat if needed) 
 Measuring the quantity of RNA using the Nanodrop spectrophotometer 
(should be blanked with Nuclease-free water before measuring). 
2.5.2 RNA integrity analysis 
 Gel preparation: put 550 µl gel matrix into a spin filter, centrifuge at 
1,500 g for 20 min at room temperature, aliquot 65 µl filtered gel into 
RNase-free microfuge tubes (store for 4 weeks maximum). 
 Preparing the Gel-Dye Mix: allow the RNA 6000 Pico dye concentrate 
to equilibrate to room temperature for 30 min, vortex for 10 s, spin 
down and add 1 µl to 65 µl filtered gel, vortex and spin at 13,000 g,     
10 min. 
 Loading the Gel-Dye Mix, RNA 6000 Pico Conditioning Solution and 
Marker according to the supplier’s instructions. 
 Load the diluted ladder and samples. 
 Vortex in the adapter supplied in the kit and run the chip under RNA 
test program in the Agilent 2100 bioanalyzer. 
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2.5.3 Reverse Transcription (RT) 
RNA samples (1 µg) were reverse transcribed using the Reverse 
Transcription System (Table 5), before reaction, the RNA sample dissolved 
in RNase-free water was incubated at 70°C for 10 min.  
Table 5: RT-PCR reaction system 
Components Volume for 1 sample (µl) 
MgCl2, 25 mM 4 
10xRT buffer 2 
dNTP mix, 10 mM 2 
Ribonuclease inhibitor 0.5 
Reverse-transcriptase (23 U/µl) 0.65 (15 U) 
Random hexamer oligodeoxyribonucleotides 0.5 
RNase-free water 10.35 
Total volume 20 
 
2.5.4 Primer design and gel electrophoresis 
Primers were designed using Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Ye, Coulouris et al. 
2012), followed by quality control applying melting curve and agarose gel 
electrophoresis analyses of the PCR products (primer nucleotide sequences 
are listed in Table 3). For separation of DNA by gel electrophoresis, use 
100 ml 2.2% agarose in 1x Tris-acetate/EDTA (TAE) buffer with 0.1 µg/ml 
ethidium bromide (EtBr solution: 10 mg/ml) with 2x12 lane comb in media 
size gel chamber to cast the gel; remove comb(s) carefully after 0.5- 1 h 
(gel should have completely solidified); fill electrophoresis chamber with 
1x TAE running buffer with 0.1 µg/ml EtBr (ca. 1 liter). After addition of 
6x Loading Solution (Fermentas, Schwerte, Germany) PCR products were 
separated by applying 80 V for ca. 1.5 h. Gel documentation was done with 
BioRad gel documentation machine using UV transillumination. 
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2.5.5 Real-time polymerase chain reaction (PCR) 
GAPDH and target gene expression in RNAs from RCC tissues were 
quantified with specific primers using the LightCycler FastStart DNA 
Master SYBR Green I kit in a LightCycler. Experiments were carried out 
according to the user instructions of the kit and run on the Light-Cycler 
using the following settings: 
Denaturation  95°C   10 min 
3-step PCR:  
Denaturation  95°C         10 s 
Annealing            60°C        10 s                     40 cycles 
Extension            72°C        16 s 
Melting curve 
Cooling 
 
Crossing points (Cp) were used to calculate relative mRNA levels using 
the formula 2-Cp. These values were normalized using the corresponding 
GAPDH mRNA levels of each sample. Normalized mean expression in 
normal tissues for each gene was used as a calibrator (expression set to 1). 
2.6 Immunochemistry (IHC) 
2.6.1 Preparation of tissue sections and cytospins 
Tissue sections (10 µm) of tissues were prepared at -20°C using a Leica 
CM3050 microtome (Leica, Wetzlar, Germany), applied to Super Frost 
Ultra Plus® slides and stored at -20°C until used. Cytospins were 
prepared with the Cytospin 2 centrifuge (SHANDON, Frankfurt, 
Germany). Briefly, prepare a cell suspension of not more than 0.5x106 
cells/ml of serum-containing medium, prepare the slides mounted with the 
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paper pad and the cuvette in the metal holder, load up to 200 µl this 
suspension in each cuvette, then spin at 800 rpm for 3 min. 
2.6.2 Staining procedure 
For immunohistochemistry, BLOXALL Blocking Solution (Vector 
Laboratories, Inc. Burlingame, CA) was used for quenching of endogenous 
peroxidase after fixation with acetone for 5 min. Then frozen sections and 
cytospins were incubated with primary antibodies followed by detection 
using ImmPRESS Universal Reagent and ImmPACT Reagent kits (Vector 
Laboratories) according to the manufacturer’s instructions. Then, tissue 
sections were counterstained using hematoxylin and covered for 
photography. 
 
2.7 Western blotting 
2.7.1 Preparation of materials and apparatus 
Materials: Cell suspension or tissue samples, lysis buffer (50 mM Tris-HCl, 
150 mM NaCl, 1% Triton X-100, pH=8.0), Complete Mini Protease 
Inhibitors Cocktail (Roche, Mannheim, Germany), ice bucket (big and 
small), cooled microcentrifuge (4°C), Nanodrop 2000 (Thermo Fisher 
Scientific, Barrington, USA), XCellSureLock Mini-Cell electrophoresis 
system (Invitrogen, NY, USA), NUPAGE Novex-Bis-Tris Gel (Invitrogen), 
Transfer buffer 20x (Invitrogen), MOPS SDS Running Buffer 20x 
(Invitrogen), 10 ml Syringe 23G 11/4 Nr. 14, distilled water, Dual Color 
Protein Marker (-20°C), 10% DTT (-20°C), 4x Loading buffer LDS, 
Thermoblock (set at 95°C), XCell II Blot Module (Invitrogen, NY, USA), 
Blotting milk buffer, Methanol, PDVF membrane 6x8 cm, Blotting pads, 
Parafilm, Electrophoresis gel, Trowel or “Blot-knife” (to open the Gel 
frames), Tweezer, Petri dishes, Ponceau dye solution, gloves, primary and 
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sencondary HRP-labeled antibodies, ECL Western Blotting System (GE, 
Freiburg, Germany), 100 ml 1x Washing buffer (T-PBS): 10 ml 10x 
PBS+90 ml dH2O+100 µl Tween 20. A dark room with scissor, timers, red 
light, exposition portfolios, HyperfilmTM ECL and development machine is 
needed for film development. 
2.7.2 Procedure 
Lysates of tissue cryosections from patients’ tissues and cells were 
prepared in lysis buffer containing Complete Mini Protease Inhibitors 
Cocktail. Protein concentrations were measured using Nanodrop 2000 for 
further use. The same amount of protein (100 µg per lane) was separated 
by SDS polyacrylamide gel electrophoresis using the XCellSureLock Mini-
Cell electrophoresis system and transferred to PDVF membranes using 
the Xcell II Blot Module. After blocking and antibody incubation of the 
membrane, the ECL Western Blotting System was used for visualization 
of bound antibodies. 
 
2.8 Microarray data analysis (dChip and GSEA) 
Probe preparation, hybridization and scanning of oligonucleotide 
microarrays (GeneChip HG U133 Plus 2.0, Affymetrix) was described 
before (Maruschke, Hakenberg et al. 2013). Briefly, Tissue samples were 
collected from RCC patients undergoing surgical resection of RCC. In total, 
there were 28 samples from primary tumor (14x grade G1, 14x grade G3), 
14 samples from normal kidney tissue (tissue samples without 
macroscopic or microscopic alterations from tumor-bearing kidney) and 32 
samples from metastases. All cases were clear-cell subtype of RCC. 
Patients did not receive systemic antitumoral treatment before surgery. 
All patients gave written informed consent, and the research was 
approved by the local ethics committees. Hybridization on oligonucleotide 
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microarrays (GeneChip HG U133 Plus 2.0, Affymetrix) was carried out 
overnight at 45°C using the Hybridization Oven 640 (Affymetrix) and 
Fluidics Station 450 (Affymetrix) following the standard protocols. 
Scanning of the microarrays was done using the GeneChip Scanner 3000 
(Affymetrix), and raw data were stored as CEL files.  
For calculation of the detection call (“absent” or “present”) the Microarray 
Suite (MAS5) algorithm was used (software: Expression Console 1.1 from 
Affymetrix). The arrays were normalized and expression values were 
calculated using the dChip algorithm that is implemented in the software 
package dChip 2010 from http://www.dchip.org (Li and Wong 2001).  
Gene set enrichment analysis (GSEA) (Subramanian, Tamayo et al. 2005) 
was used to determine the coordinate expression of a set of 46 EMT-
associated genes which have been described to be up-regulated during 
EMT (Table 6). The GSEA software is available at 
http://www.broadinstitute.org/gsea for download. Briefly, GSEA compares 
gene expression in biological samples, e.g. primary tumor and normal 
tissue. Briefly, genes are ranked according to their signal-to-noise ratio 
(sum of the means of the gene in both groups divided by sum of the 
standard deviations). The algorithm calculates the running enrichment 
score (ES) by walking through the ranked list. The ES starts with zero, 
and it is increased each time when a gene is member of the gene set and 
decreased when it is not. The maximum deviation from zero is the final ES. 
When the genes of a gene set are enriched at one side of the ranked list 
(i.e., the majority is either up-regulated or down-regulated), then the final 
ES is high, indicating a meaningful up- or down-regulation of the gene set 
(pathway). The statistical significance (nominal P value) of the ES is 
calculated by using an empirical phenotype-based permutation test 
procedure. When an entire database of gene sets is evaluated, the 
estimated significance level is adjusted to account for multiple hypothesis 
testing. 
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2.9 Statistics 
The unpaired two-tailed Mann-Whitney U test was used to compare gene 
expression levels between tumors of different stage and grade (TNMG 
classification). Statistical differences between transcript levels of normal 
kidney, primary tumor and metastases were analyzed using Kruskal-
Wallis analyses with subsequent post-hoc tests. For survival analyses, the 
optimal cut-off value for each gene was determined using martingale 
residuals as described (Therneau 1990). Briefly, the martingale residual 
from a univariate Cox model exploring each gene was plotted on the y-axis 
against the respective gene expression value on the x-axis, and a smooth 
fit using the LOWESS (locally weighted scatterplot smoothing) function 
was calculated. The optimal cut-off was the expression value where the 
fitting line crossed zero on the y-axis. The low-risk and high-risk patient 
subgroups defined by this optimized cut-off value were further analyzed 
using univariate and multivariate methods. Outcome was evaluated using 
the Kaplan-Meier method and log-rank test. The starting point of follow-
up was the time of surgery and the endpoint was cancer-specific survival. 
Additionally, multivariate Cox regression models were built which 
included mRNA expression levels of selected genes, TNM stage, and 
pathological tumor grade. Statistical calculations were performed using 
the software packages Prism 6.0 (GraphPad, San Diego, USA), R 2.15 
(http://www.R-project.org/) and MedCalc 12.0 (MedCalc, Mariakerke, 
Belgium). p<0.05 was defined to be statistically significant. 
RESULTS 
28 
 
3. Results 
3.1 Microarray data analysis of EMT-related genes 
3.1.1 Creation of EMT gene set list by database searching 
By reviewing the former studies on EMT and solid tumors through 
PubMed searching, a gene list containing genes which were reported to be 
up-regulated in tumor undergoing EMT process was created. These genes 
encode adhesion molecules, transcription factors, chemokine receptors, 
metalloproteinases and others. The detailed gene list is shown in Table 6, 
genes are ranked by the enrichment score from highest to lowest obtained 
from gene set enrichment analysis.  
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Table 6: GSEA analysis of EMT-related genes and quantitative RT-PCR 
       
Rank 
Gene 
symbol 
Probe set Gene name (Alternative name) 
Functional 
category (Gene 
Atlas) 
Mean mRNA 
levels in 
normal 
kidney  
(n=14) 
Mean 
mRNA 
levels in 
primary 
tumor 
(n=28) 
Fold change        
primary  
tumor/normal  
(microarray) 
Fold change 
primary 
(n=55)/  
normal 
(n=19) (qRT-
PCR)  
Reference for role in EMT 
1 VIM 201426_s_at vimentin structural protein 5815 14765 2.5 1.5 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Asiedu, Ingle et al. 2011) 
2 SPARC 200665_s_at 
secreted protein, acidic, cysteine-
rich (osteonectin) 
chaperone/stress , reg
ulatory , structural 
protein , tumor 
suppressor 3649 9941 2.7 n.d. 
(Asiedu, Ingle et al. 2011, 
Thomson, Petti et al. 2011) 
3 CXCR4 217028_at 
chemokine (C-X-C motif), receptor 
4 (fusin) receptor membrane G 491 4443 9.0 1.9 (Li, Ma et al. 2012) 
4 TGFB1 203085_s_at transforming growth factor, beta 1 
regulatory , signaling
growthfactor 319 1524 4.8 n.d. 
(Kalluri and Neilson 2003, 
Thiery, Acloque et al. 2009, 
Asiedu, Ingle et al. 2011) 
5 FN1 211719_x_at fibronectin 1 adhesion 1586 8944 5.6 1.7 
(Zeisberg and Neilson 2009, 
Asiedu, Ingle et al. 2011) 
6 CXCR7 212977_at 
chemokine (C-X-C motif) receptor 
7 receptor membrane G 285 2530 8.9 3.3 
(Asiedu, Ingle et al. 2011, Li, 
Ma et al. 2012) 
7 TMEFF1 205122_at 
transmembrane protein with 
EGF-like and two follistatin-like 
domains 1 tumor suppressor 32 145 4.6 n.d. (Thomson, Petti et al. 2011) 
8 ITGA5 201389_at 
integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) adhesion , receptor 297 1090 3.7 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Asiedu, Ingle et al. 2011) 
9 ETS1 224833_at 
v-erythroblastosis virus E26 
oncogene homolog 1 (avian) transcription factor 1503 3656 2.4 n.d. (Zeisberg and Neilson 2009) 
10 TIMP1 201666_at 
TIMP metallopeptidase  
inhibitor 1 enzyme 2833 9136 3.2 n.d. (Asiedu, Ingle et al. 2011) 
11 TCF4 203753_at transcription factor 4 (E2-2) transcription factor 568 1961 3.5 n.d. (Thiery, Acloque et al. 2009) 
12 
SERPINH
1 207714_s_at 
serpin peptidase inhibitor, clade 
H (heat shock protein 47), 
member 1, (collagen binding 
protein 1) enzyme 477 1917 4.0 n.d. (Zeisberg and Neilson 2009) 
13 CDH2 203440_at 
cadherin 2, type 1, N-cadherin 
(neuronal) adhesion 1198 1988 1.7 9.1 
(Thiery, Acloque et al. 2009, 
Zeisberg and Neilson 2009) 
14 GNG11 204115_at 
guanine nucleotide binding 
protein (G protein), gamma 11 receptor 2497 4617 1.8 n.d. (Asiedu, Ingle et al. 2011) 
15 MSN 200600_at moesin structural protein 3490 4931 1.4 n.d. 
(Haynes, Srivastava et al. 
2011) 
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Rank 
Gene 
symbol 
Probe set Gene name (Alternative name) 
Functional 
category (Gene 
Atlas) 
Mean mRNA 
levels in 
normal 
kidney  
(n=14) 
Mean 
mRNA 
levels in 
primary 
tumor 
(n=28) 
Fold change        
primary  
tumor/normal  
(microarray) 
Fold change 
primary 
(n=55)/  
normal 
(n=19) (qRT-
PCR)  
Reference for role in EMT 
16 CDH11 207173_x_at 
cadherin 11, type 2, OB-cadherin 
(osteoblast) adhesion 517 1508 2.9 n.d. (Zeisberg and Neilson 2009) 
17 COL3A1 201852_x_at 
collagen, type III, alpha 1 (Ehlers-
Danlos syndrome type IV, 
autosomal dominant) structural protein 1630 4899 3.0 n.d. (Asiedu, Ingle et al. 2011) 
18 COL5A2 221729_at collagen, type V, alpha 2 structural protein 158 1453 9.2 n.d. (Asiedu, Ingle et al. 2011) 
19 ITGAV 202351_at 
integrin, alpha V (vitronectin 
receptor, alpha polypeptide, 
antigen CD51) adhesion 3004 4612 1.5 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009) 
20 ACTA2 200974_at 
actin, alpha 2, smooth muscle, 
aorta (α-SMA) structural protein 3176 6606 2.1 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009) 
21 LAMA5 210150_s_at laminin, alpha 5 adhesion 128 287 2.2 n.d. (Zeisberg and Neilson 2009) 
22 ZEB1 212764_at 
zinc finger E-box binding 
homeobox 1; transcription factor 8 
(represses interleukin 2 
expression) transcription factor 884 1507 1.7 13.8 
(Liu, El-Naggar et al. 2008, 
Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Thomson, Petti et al. 2011) 
23 FOXC2 214520_at 
forkhead box C2 (MFH-1, 
mesenchyme forkhead 1) transcription factor 21 29 1.4 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009) 
24 DES 202222_s_at desmin locomotion 108 163 1.5 n.d. (Kalluri and Weinberg 2009) 
25 PDGFRB 202273_at 
platelet-derived growth factor 
receptor, beta polypeptide receptor 273 641 2.3 n.d. (Asiedu, Ingle et al. 2011) 
26 TGFB2 228121_at transforming growth factor, beta 2  
signaling, cytokine 
growth factor 170 411 2.4 n.d. 
(Kalluri and Weinberg 2009, 
Thiery, Acloque et al. 2009, 
Asiedu, Ingle et al. 2011) 
27 CALD1 212077_at caldesmon 1 structural protein 4492 6397 1.4 n.d. (Thomson, Petti et al. 2011) 
28 TCF3 210776_x_at 
transcription factor 3 
(E12/E47/E2A) transcription factor 418 717 1.7 n.d. 
(Kalluri and Weinberg 2009, 
Thiery, Acloque et al. 2009) 
29 S100A4 203186_s_at S100 calcium binding protein A4 regulatory 1018 2467 2.4 0.5 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Thomson, Petti et al. 2011) 
30 COL1A2 202403_s_at collagen, type I, alpha 2 structural protein 2071 5319 2.6 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Asiedu, Ingle et al. 2011) 
31 SERPINE1 202627_s_at 
serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 enzyme 216 2342 10.8 n.d. 
(Liu, El-Naggar et al. 2008, 
Asiedu, Ingle et al. 2011) 
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Rank 
Gene 
symbol 
Probe set Gene name (Alternative name) 
Functional 
category (Gene 
Atlas) 
Mean mRNA 
levels in 
normal 
kidney  
(n=14) 
Mean 
mRNA 
levels in 
primary 
tumor 
(n=28) 
Fold change        
primary  
tumor/normal  
(microarray) 
Fold change 
primary 
(n=55)/  
normal 
(n=19) (qRT-
PCR)  
Reference for role in EMT 
32 AHNAK 211986_at 
AHNAK nucleoprotein 
(desmoyokin) cell organization 3550 4708 1.3 n.d. (Thomson, Petti et al. 2011) 
33 LEF1 221558_s_at 
lymphoid enhancer- 
binding factor 1 transcription factor 187 512 2.7 n.d. 
(Thiery, Acloque et al. 2009, 
Zeisberg and Neilson 2009) 
34 ZEB2 205063_at 
zincfinger E-box binding 
homeobox 2 (SIP1, ZFHX1B) transcription factor 111 260 2.3 0.8 
(Kalluri and Weinberg 2009, 
Thiery, Acloque et al. 2009, 
Thomson, Petti et al. 2011) 
35 MMP9 203936_s_at 
matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) enzyme 123 1166 9.5 1.0 
(Kalluri and Weinberg 2009, 
Asiedu, Ingle et al. 2011) 
36 TWIST1 213943_at 
twist homolog 1 
(acrocephalosyndactyly 3; 
Saethre-Chotzen syndrome) 
(Drosophila) transcription factor 50 112 2.2 0.9 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009, 
Thomson, Petti et al. 2011) 
37 DDR2 227561_at 
discoidin domain receptor tyrosine 
kinase 2 
regulation of  cell 
proliferation 531 621 1.2 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009) 
38 CTNNB1 201533_at 
catenin (cadherin-associated 
protein), beta 1, 88kDa regulatory, signaling 2539 2929 1.2 n.d. 
(Thiery, Acloque et al. 2009, 
Zeisberg and Neilson 2009, 
Thomson, Petti et al. 2011) 
39 SNAI1 219480_at snail homolog 1 (Drosophila) transcription factor 119 154 1.3 n.d. 
(Kalluri and Weinberg 2009, 
Thiery, Acloque et al. 2009, 
Zeisberg and Neilson 2009) 
40 SNAI2 213139_at snail homolog 2 (Drosophila) transcription factor 424 576 1.4 0.6 
(Kalluri and Weinberg 2009, 
Thiery, Acloque et al. 2009, 
Zeisberg and Neilson 2009) 
41 MMP2 201069_at 
matrix metallopeptidase 2 
(gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) enzyme 826 928 1.1 0.4 (Kalluri and Weinberg 2009) 
42 MMP3 205828_at 
matrix metallopeptidase 3 
(stromelysin 1, progelatinase) enzyme 14 14 1.0 n.d. (Kalluri and Weinberg 2009) 
43 GSC 1552338_at goosecoid homeobox transcriptionfactor 5 4 0.8 n.d. 
(Kalluri and Weinberg 2009, 
Zeisberg and Neilson 2009) 
44 FOXD3 241612_at forkhead box D3 transcriptionfactor 18 9 0.5 n.d. (Kalluri and Weinberg 2009) 
45 IGFBP4 201508_at 
insulin-like growth factor binding 
protein 4 
signaling, cytokine 
growth factor 4919 3714 0.8 n.d. (Thomson, Petti et al. 2011) 
46 SDC1 201286_at syndecan-1 
structural protein , 
protooncogene,  
signaling 2747 1266 0.5 n.d. (Zeisberg and Neilson 2009) 
(END) 
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3.1.2 EMT genes are preferentially expressed in primary kidney 
tumors – Gene Set Enrichment Analysis (GSEA) 
Raw data from previously described microarray study (Maruschke, 
Hakenberg et al. 2013) were used and included 42 samples from RCC 
patients (14 normal renal tissues from tumor-bearing kidneys, 14 G1 
grade primary tumors, and 14 G3 grade primary tumors). GSEA was 
performed using the EMT gene set, a list of up-regulated genes in the 
process of EMT, to determine with confidence whether this set of 
functionally linked genes is coordinately up- or down-regulated between 
groups of biological samples.  
GSEA in 28 primary tumors and 14 normal kidney tissues showed that 
expression of the EMT gene set was significantly enriched (up-regulated) 
in primary tumors compared to normal kidney tissues (false discovery rate 
(FDR)=0.01, nominal p<0.05; Figure 2A). Out of the 46 EMT gene set 
genes, 34 genes contributed to the core enrichment and exhibited on 
average 3.4-fold higher expression (range 1.3 to 10.8 fold) in RCC 
compared to normal kidney (Table 6). Among the top-ranked genes (those 
with a higher signal/noise ratio) were genes such as CXC chemokine 
receptor 4 (CXCR4; fold change (fc) = 9.0), CXCR7 (fc=8.9), fibronectin 
(FN1; fc=5.6), transforming growth factor β1 (TFGB1; fc=4.8) and 
vimentin (VIM; fc=2.5) with well-defined functions in EMT and tumor 
stem cell biology. In contrast, comparison between G1 and G3 grade 
primary tumors did not reveal significant differences (FDR=0.84, Figure 
2B). 
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Figure 2: Gene set enrichment analysis (GSEA) of EMT-associated 
genes in RCC. Genes were ranked according to their differential expression 
between (A) normal kidney (n=14) and primary RCC (n=28) and (B) G1 
primary RCC (n=14) and G3 primary RCC (n=14). Expression levels were 
determined by oligonucleotide microarray analysis. Red bars indicate genes 
expressed preferentially in normal tissues and G1 primary tumors, blue bars 
genes overexpressed in primary tumors and G3 primary tumors with color 
intensity corresponding to the degree of overexpression (dark > light). Black 
bars below the graph mark the position of the set of 46 genes up-regulated 
during EMT. Significant enrichment of this gene set was observed with the 
majority of the genes being higher expressed in primary tumors than in 
normal kidney (FDR 0.012); no enrichment was seen for the G1/G3 primary 
tumor comparison (FDR 0.844). ES, enrichment score; FDR, false discovery 
rate; NES, normalized enrichment score. 
3.1.3 Expression pattern of EMT-related genes in different groups 
of samples – microarray analysis 
Normalized genome-wide gene expression data were further analyzed 
using dChip. The overall expression pattern of EMT genes is shown as 
heat map in Figure 3 created by GSEA (listed from top to bottom are the 
least to the most up-regulated genes in primary tumor).  
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Figure 3: Heat Map by GSEA. Gene expression of each gene from EMT-
related gene list is shown (14 normal kidneys and 28 primary tumors). Red: 
up-regulation, blue: down-regulation. 
Comparison of the expression levels of individual genes in normal kidney 
tissue and primary tumor as well as in G1 and G3 grade primary tumors 
are shown in Figure 4: FN1, ITGA5, LEF1, MMP9, S100A4, SERPINE1, 
TGFB1 and TIMP1 represent higher expression in primary tumor 
compared to normal kidney, while gene expression in G3 primary tumors 
is higher than that in G1 primary tumors (Figure 4A-H). CDH1, encoding 
E-cadherin, has an opposite expression pattern as the eight genes (Figure 
High Low 
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4I).Additionally to the 8 of 46 genes mentioned above, another 27 genes 
have also significantly increased expression in overall primary tumors 
(G1/G3) compared to normal kidney tissues while no significant difference 
between G1 and G3 grade tumors was found (Figure 5, shown in two 
separated parts). 
 
Figure 4: Box plots of genes with significantly increased 
expression in primary tumors compared to normal kidney, and 
increased expression in G3 grade primary tumors compared to G1 
grade tumors. The results are shown as box plots with median and 25 
and 75 percentiles or as dot plots. Whiskers mark the maximum and 
minimum values. P values below the graphs indicate the overall statistical 
significance determined by Kruskal-Wallis analyses. Individual statistical 
significance is depicted by brackets and asterisks. *, p<0.05; **, p<0.01. N, 
normal renal tissue from tumor-bearing kidney; P, primary tumor; M, 
metastases; G1/G3, tumor grade. 
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Figure 5 (part I): Box-plots of genes which have significantly 
increased expression in primary tumors compared to normal kidney, 
but have no significantly increased expression in G3 primary tumors 
compared to G1 primary tumors. The results are shown as box plots with 
median and 25 and 75 percentiles or as dot plots. Whiskers mark the 
maximum and minimum values. P values below the graphs indicate the 
overall statistical significance determined by Kruskal-Wallis analyses. 
Individual statistical significance is depicted by brackets and asterisks. *, 
p<0.05; **, p<0.01. N, normal renal tissue from tumor-bearing kidney; P, 
primary tumor; M, metastases; G1/G3, tumor grade. 
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Figure 5 (part II): Box-plots of genes which have significant 
increased expression in primary tumors compared to normal kidney, 
but have no significantly increased expression in G3 primary tumors 
compared to G1 primary tumors. The results are shown as box plots with 
median and 25 and 75 percentiles or as dot plots. Whiskers mark the 
maximum and minimum values. P values below the graphs indicate the 
overall statistical significance determined by Kruskal-Wallis analyses. 
Individual statistical significance is depicted by brackets and asterisks. *, 
p<0.05; **, p<0.01. N, normal renal tissue from tumor-bearing kidney; P, 
primary tumor; M, metastases; G1/G3, tumor grade. 
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3.1.4 Prognostic significance of EMT-related gene expression in 
RCC patients based on microarray data 
For each gene, Kaplan-Meier curves were drawn to evaluate the predictive 
power of EMT-related genes in patient outcome. In primary tumors, 
correlation of gene expression and patient outcome was analyzed and 
genes that have a potential predictive role are shown in Figure 6 (genes 
are ranked from smallest to largest p value, genes with a p<0.20 are 
shown).  
To test whether transcript levels of additional EMT-associated genes could 
potentially serve as outcome predictors, we correlated mRNA levels of the 
46 EMT-related genes of the set of primary tumors (n=28) used for 
transcriptome analysis with tumor-specific survival. Higher mRNA levels 
of 7 of the genes investigated correlated significantly with poor survival 
(TGFB1), serpin peptidase inhibitor (SERPINE1), integrin α5 (ITGA5), 
transcription factor 3 (TCF3), FN1, MMP9, TIMP metallopeptidase 
inhibitor 1 (TIMP1); p between 0.001 and 0.020. Higher CDH1 transcript 
levels predicted significant better outcome (p=0.009; Figure 6A-H). 
Another subset of 7 mRNAs including VIM and MMP2 transcripts 
exhibited p values between 0.05 and 0.18 (Figure 6I-O).  
In summary, lower expression of CDH1 and higher expression of TGFB1, 
SERPINE1, ITGA5, TCF3, FN1, MMP9 and TIMP1 predict poor outcome 
of RCC patients in univariate survival analysis. 
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Figure 6: Kaplan-Meier survival analysis of RCC patients based on 
EMT-related gene expression determined by transcriptome analyses 
in primary tumor samples. Oligonucleotide microarray expression data 
from primary tumors of a total of 28 patients for the set of 46 EMT-associated 
genes and cancer-specific survival time were used for calculation (10 deaths 
occurred during the observation period). Cancer-specific death is used as 
endpoint. Median mRNA levels were used as cut-off. Low mRNA level groups 
are represented as blue (low expression), high level groups as red curves (high 
expression). P values for each gene are included in the graphs. Results are 
only shown for p<0.2. p value <0.05 were considered significant.  
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3.2 PCR validation of selected genes 
3.2.1 Expression of selected genes 
To validate differential expression of EMT-related genes in normal renal 
tissues and primary RCC and to determine whether these genes are 
similarly deregulated in metastases, we performed quantitative PCR 
analyses using RNA from normal renal tissue, primary tumors and 
metastases from an independent cohort of RCC patients. We selected a 
subset of the EMT-related genes which were found to be among the top 
ranked genes in the GSEA analysis or are known to represent master 
transcriptional regulators in other tumor entities or have been shown to 
be functionally important for tumor progression like extracellular matrix-
degrading metalloproteinase (Table 6) as well as CDH1, the down-
regulation of which is considered a hallmark of EMT(De Craene and Berx 
2013). 
Five out of the 13 analyzed genes i.e. CXCR4, CXCR7, VIM, CDH2 
(encoding N-cadherin) and ZEB1 (zinc finger E-box binding homeobox 1) 
were up-regulated in primary RCC compared to normal tissue (Figure 7A-
F). In metastases, even higher median mRNA levels were found for VIM, 
CXCR4 and FN1 (Figure 7A, B, D). Interestingly, compared to primary 
tumors lower mRNA levels were observed in metastases for CXCR7, ZEB1 
and CDH2 (p<0.001, Figure 7C, E, F). These findings could indicate 
reversal of EMT during metastasis. CDH1 was down-regulated in primary 
tumors and metastases compared to normal kidney tissues. 
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Figure 7: EMT-associated gene expression during RCC progression. (A-
G) Normalized transcript levels of the indicated genes were determined by real-
time PCR after reverse transcription of total RNA from normal renal tissue 
from tumor-bearing kidney (N), primary tumor (P) and metastases (M). The 
mean value of normalized expression in normal tissue was used as the 
calibrator (set to 1). To identify a potential cadherin switch, the ratio of 
CDH2/CDH1 mRNA content was calculated for each sample (H). The results 
are shown as box plots with median and 25 and 75 percentiles. Whiskers mark 
the maximum and minimum values. P values below the graphs indicate the 
overall statistical significance determined by Kruskal-Wallis analyses. 
Individual statistical significance is depicted by brackets and asterisks. *, 
p<0.05; **, p<0.01. 
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3.2.2 Cadherin switch is observed in primary tumors and reversed 
in metastases 
Loss of CDH1 expression resulting in disruption of tight junctions and 
concomitant gain of cell motility is typically observed during EMT. 
Another characteristic feature of the EMT process is increased expression 
of the cell adhesion molecule N-cadherin (encoded by CDH2) which is often 
observed in parallel. This inverse regulation of expression of CDH1 and 
CDH2 is referred to as cadherin switch (Gravdal, Halvorsen et al. 2007). 
We found that CDH1 had on average lower expression levels both in 
primary RCC tumors and metastases compared to normal tissue (p<0.01), 
while CDH2 was up-regulated in primary tumors compared to normal 
tissue and down-regulated in metastases compared to primary tumors 
(Figure 6F, G). For each tissue sample, the ratio of CDH2/CDH1 mRNA 
levels was calculated. The ratio in primary tumors was significantly 
higher than in normal kidney samples (p<0.01, Figure 6H). In metastases, 
the ratio was significantly lower compared to primary tumors (p<0.01, 
Figure 6H). 
3.2.3 Prediction of patient outcome based on EMT-associated 
genes expression 
3.2.3.1 Kaplan-Meier analysis (univariate analysis) 
For 49 out of 55 patients follow-up data were available and were used for 
survival analysis. The Kaplan-Meier analyses revealed that higher mRNA 
expression levels of VIM, CXCR4 (both p<0.001), FN1 (p=0.02) and 
TWIST1 (p=0.037) in primary RCC were associated with a worse outcome 
(Figure 8A-D). Increased MMP2 mRNA levels were also associated with a 
worse outcome, but the differences were not significant (p=0.101; Figure 
8F). 
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3.2.3.2 Multivariate Cox regression model 
A multivariate Cox regression model was established using prognostic 
factors such as TNM stage, pathological grade and mRNA levels of 
selected genes. The multivariate analysis was carried out with data from 
44 patients with complete datasets because in some patients the presence 
of lymph node metastases was unknown (pNX). Up-regulation of CXCR4 
and VIM mRNA in primary tumors were independent prognostic markers 
(p=0.042 and p=0.008, respectively) for an unfavorable outcome in RCC 
patients (Table 7). 
 
Figure 8: Kaplan-Meier survival analysis of RCC patients based on 
EMT-related gene expression determined by RT-PCR in primary 
tumor samples. Expression data from primary tumors of a total of 49 
patients and cancer-specific survival time were used for calculation (28 deaths 
occurred during observation period). Cancer-specific death is used as endpoint. 
Low mRNA level groups are represented as blue, high level groups as red 
curves. Patients at risk at 0, 12, 36, 60 and 120 months after surgery are 
shown below the graphs. P values for each gene are included in the graphs. 
p<0.05 were considered significant. Genes with a p ≤0.1 are shown. 
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Table 7: Determination of prognostic power of pathological and clinical 
parameters and EMT gene mRNA levels in primary tumor by 
multivariate Cox regression analysis 
 Hazard 
ratio 
95% confidence interval p value*† 
T1-2 vs.T3-4 1.5 0.5 – 4.4 0.483 
N0 vs. N+ 1.1 0.3 – 3.7 0.929 
M0 vs. M1 5.2 1.7 – 16.1 0.004 
G1-2 vs. G3 0.6 0.2 – 2.2 0.436 
VIM low vs. high 
CXCR4 low vs. high 
7.6 
3.8 
1.7 – 34.4 
1.1 – 13.9 
0.008 
0.042 
* 44 patients, 23 events during follow-up; endpoint: tumor-specific survival, †p 
values < 0.05 are shown in bold 
 
3.3 Expression and prognostic value of TPBG and CXCR4 in RCC 
 
CXCR4 was shown above to be an independent prognosis marker and 
proven by our group as a stem cell marker in renal cell carcinoma 
(Gassenmaier, Chen et al. 2013). The overexpression of CXCR4 was found 
to be correlated with metastasis, migration, cell renewal and proliferation 
(Domanska, Kruizinga et al. 2013). Two other molecules, CXCL12 and 
TPBG, are important for CXCR4 function. CXCL12 is known as ligand of 
CXCR4, while TPBG, also named 5T4, was reported to be critical for the 
surface expression of CXCR4. 
3.3.1 Expression of CXCR4 in RCC 
So far, expression of CXCR4 has only been analyzed at the mRNA level. In 
order to prove the presence of CXCR4 protein, immunohistochemistry and 
Western blot analyses were carried out using either tissue samples from 
patients or cytospins. HEK-293T cells transfected with a CXCR4 
expression plasmid and un-transfected HEK-293T cells served as positive 
and negative controls, respectively. Staining with an anti-CXCR4 antibody 
revealed that CXCR4-transfected HEK-293T cells had a high proportion of 
positive cells while the un-transfected cells were totally negative after 
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staining (Figure 9A, B). In general, a higher number of CXCR4-positive 
cells were observed in primary tumors and metastases compared to 
normal kidney tissues (Figure 9C-E). Furthermore, CXCR4 expression 
was found to agree well at the mRNA and protein level as determined by 
real-time PCR and Western blot, respectively (Figure 9F, G). 
 
Figure 9: Correlation of CXCR4 mRNA and protein levels in cell 
lines, normal kidney and RCC tissues: Immunohistochemistry 
staining of CXCR4 in (A) HEK-293T cells, (B) CXCR4-transfected HEK-
293T cells, (C) normal kidney, (D) primary tumor and (E) RCC lung 
metastasis; GAPDH-normalized expression of CXCR4 as determined by 
real-time PCR (F); Western Blot detection of CXCR4 (G): Normal tissue 
(N1 and N2), primary tumors with low CXCR4 expression (P1 and P2), 
primary tumors with high CXCR4 expression (P3 and P4), and metastasis 
(M1). Scale bar=200 µm.  
 
3.3.2 Expression and prognostic significance of TPBG in RCC 
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Expression of TPBG was also measured by real-time PCR and IHC. 
Expressions of TPBG in primary tumors are higher than that in normal 
kidney samples and metastases (Figure 10A, overall p<0.001). Two 
primary tumor samples were excluded from expression and survival 
analysis because they were clearly defined as outliers regarding the 
expression of TPBG. Lower TPBG mRNA level indicate a better outcome 
of RCC patients (Figure 10B, p=0.036). TPBG expression level was an 
independent prognostic marker in RCC patients according to Cox 
regression model (Table 8, p=0.037). 
 
Figure 10: Expression and prognostic significance of TPBG in RCC 
patients. (A) mRNA expression of TPBG determined by real-time PCR in 
19 normal kidney tissues (N), 50 primary tumors (P) and 38 metastases (M); 
(B) TPBG expression correlates with patient outcome (Kaplan-Meier 
analysis). Median expression was used as cut-off of high/low expression. 
 
Table 8: Multivariate analysis of TPBG expression with TNM stage and 
pathological grade (Cox regression model) 
Covariate Hazard ratio 95% confidence interval p value*† 
T1-2 vs.T3-4 0.8 0.3-2.3 0.742 
N0 vs. N+ 2.3 0.9-6.0 0.100 
M0 vs. M1 3.2 1.0-9.8 0.042 
G1-2 vs. G3 2.2 0.8-5.9 0.120 
TPBG low vs. high 2.7 1.1-6.8 0.037 
* 44 patients, 23 events during follow-up; †p values < 0.05 are shown in bold 
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HEK-293T cells were transfected with expression plasmid of CXCR4 and 
TPBG to verify the specificity of fluorescent antibodies used. The gating 
strategy is shown in Figure 11. Un-transfected HEK293T cells were taken 
for example.  
 
 
Figure 11: Gating strategy for transfected and untransfected 
HEK-293T cells. (A) Firstly, the main population is gated in a FSC-H vs. 
SSC-H plot to exclude debris located in the lower left corner; (B) in a FSC-
H vs. FL3-H plot, 7-AAD-positive cells (high fluorescence FL3; dead cells) 
are excluded; (C) the negative control HEK-293T cells (no anti-CXCR4 or 
anti-TPBG antibodies) were used to exclude the influence of auto-
fluorescence of cells; (D) compensation: single stained control HEK-293T 
cells were used to avoid potential interfere of fluorescence of APC-
conjugated anti-TPBG antibodies (FL4); (E) the percentage of HEK-293T 
cells positively stained for CXCR4 in CXCR4/TPBG double-stained cells. 
The unit for proportion in the figure is percentage (%). 
 
CXCR4-transfected HEK-293T cells have a highly increased proportion of 
CXCR4-positive cells in comparison with un-transfected HEK-293T cells 
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(from 1.5% to 76.6%). TPBG-transfected HEK-293T cells also have an 
obviously higher proportion of TPBG-positive cells than un-transfected 
HEK-293T cells (Figure 12A, B). 
After verifying the specificity of antibodies, SK-RC-17 and RCC53 cell 
lines were stained by APC-conjugated anti-TPBG and PE-conjugated anti-
CXCR4 antibodies to investigate the potential co-localization of the two 
molecules on the cell surface. However, very low proportions of cells in 
both cell lines are double positive and no obvious sub-population of double-
positive cells was found (Figure 12C, D). 
 
Figure 12: Antibodies specificity verification and double staining of 
TPBG and CXCR4 in RCC cell lines. Un-transfected HEK293T cells and 
TPBG (A) or CXCR4 transfected HEK293T cells (B) were counted by flow 
cytometry; double-stained renal cell carcinoma cell line RCC53 (C)  and SK-RC-
17 (D). The number of cells in each quadrant is indicated as percentage of total 
viable cells. 
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3.4 Genes consecutively higher expressed during tumor 
progression can predict survival 
Analysis of microarray expression data from normal kidney, primary 
tumors and metastases revealed that for 59 probe sets (genes) there was 
increased expression in primary RCC compared with normal kidney, and 
at the same time in metastases compared with primary tumors (criteria: 
2-fold difference each and p<0.05). In uni- or multivariate survival 
analysis, increased expression of 15 of these probe sets was significant. 
Undefined genes (C1orf216 and Hs.133294.1) and genes with very low 
mRNA level in RT-PCR (NDC80, GOLSYN, DTL, and BUB1B) were 
excluded. Eight genes (TOP2A, SFN, CENPF, AMPD3, ATAD2, AURKA, 
HELLS and TET3) were validated by quantitative RT-PCR. Multivariate 
survival analysis in an independent validation cohort of 52 primary RCCs 
showed that TOP2A (HR=4.4, p=0.004), TET3 (HR=2.9, p=0.031), HELLS 
(HR=3.6, p=0.007), and ATAD2 (HR=3.8, p=0.014) represent independent 
prognostic predictors for RCC patients.  
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4. Discussion 
4.1 EMT takes place in RCC 
Changes of cell morphology and the state of cell differentiation play an 
important role in embryogenesis and carcinogenesis (Boyer, Tucker et al. 
1988, Thiery, Boyer et al. 1988). The conversions of epithelial cells to 
mesenchymal cells, named EMT, are commonly found in epithelial-origin 
carcinoma such as breast cancer (Yang, Liu et al. 2013), lung cancer 
(Zhang, Liu et al. 2013), gastrointestinal cancer (Teixido, Mares et al. 2013, 
Xia, Ooi et al. 2013, Zhao, Li et al. 2013, Zhu, Gao et al. 2013), squamous 
cell carcinoma (Yang, Chang et al. 2007), ovarian cancer (Ahmed, 
Abubaker et al. 2010), cervical cancer (Yan, Wang et al. 2013) and 
urological cancers (Wang, Fang et al. 2013, Zhu, Zhu et al. 2013). Since 
there is almost no knowledge so far about the role of EMT in RCC and 
about its impact on patients’ prognosis, 46 EMT-related genes were 
selected from the literature and analyzed in RCC patients in this study.  
By analyzing oligonucleotide microarray data using GSEA, 34 genes from 
a set of 46 genes known to be up-regulated during the EMT process were 
found to be significantly enriched in RCC compared to normal renal tissue, 
indicating an important role of EMT in RCC. Out of the 46 genes, 42 genes 
exhibited increased mRNA levels in primary RCC compared to normal 
kidney tissue with 26 genes showing a change larger than 2-fold (Table 6). 
Up-regulation of gene expression could be confirmed by RT-PCR for 5 out 
of 12 genes which were selected for validation in an independent cohort of 
RCC patients (Figure 7). This is further supported by the switch from E-
cadherin to N-cadherin expression between normal kidney and primary 
RCC which is characteristic for EMT (Gravdal, Halvorsen et al. 2007).  
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TWIST (an activator of CDH2 which encodes N-cadherin), SNAIL2 (also 
known as SLUG, a repressor of CDH1 encoding E-cadherin) and the 
extracellular proteases matrix metalloproteinase 2 (MMP2) and 9 (MMP9) 
are classical EMT markers and serve as effectors of EMT. Increased 
expression of MMP2 and MMP9 was verified in renal cell carcinoma to be 
correlated with poor prognosis (Kallakury, Karikehalli et al. 2001). Zinc 
finger E-box binding homeobox 1 (ZEB1) and 2 (ZEB2) are proposed to be 
EMT-activators functioning as transcriptional repressors of E-cadherin 
expression (Aigner, Dampier et al. 2007). S100A4/FSP1 is known as a 
facilitator of EMT and is used as a marker for epithelial cells undergoing 
early-stage EMT (Okada, Danoff et al. 1997, Teng, Zeisberg et al. 2007). 
The prognostic significance of S100A4 expression was demonstrated for 
human breast cancer and renal cell carcinoma (Rudland, Platt-Higgins et 
al. 2000, Bandiera, Melloni et al. 2009). CXC chemokine receptor 4 
(CXCR4) is recognized as an stem cell marker in renal cell carcinoma 
(Gassenmaier, Chen et al. 2013), the role of CXCR4 signaling in tumor 
invasion and metastases was proved in lung cancer, pancreatic cancer and 
also in renal cell carcinoma (Pan, Mestas et al. 2006, D'Alterio, Barbieri et 
al. 2012, Li, Ma et al. 2012). CXCR4 signaling can induce epithelial-
mesenchymal transition in squamous cell carcinoma (Onoue, Uchida et al. 
2006). Interestingly, von Hippel-Lindau tumor suppressor (pVHL) can 
down-regulate CXCR4 and coordinately regulate MMP2/MMP9 expression 
(Staller, Sulitkova et al. 2003, Struckmann, Mertz et al. 2008). CXCR7 can 
heterodimerize with CXCR4 and both receptors share the same ligand, 
CXCL12. CXCR7 was also shown to induce EMT in bladder cancer (Hao, 
Zheng et al. 2012). Fibronectin (encoded by FN1) is a glycoprotein 
expressed at the cell surface and in the extracellular matrix, and Vimentin 
(encoded by VIM) is a type III intermediate filament and part of the 
cytoskeleton of mesenchymal cells and is also known as a classical EMT 
marker (Chaw, Majeed et al. 2012). Both fibronectin and vimentin levels 
DISCUSSION 
52 
 
were reported to increase during the process of EMT (Mani, Guo et al. 
2008). 
During our project, one study also validated increased expression of some 
mesenchymal markers in RCC by immunohistology (Harada, Miyake et al. 
2012). In addition, EMT in RCC was reported to be regulated by tumor 
necrosis factor-alpha microRNA-30c and microRNA-200s (Ho, Tang et al. 
2012, Huang, Yao et al. 2013, Yoshino, Enokida et al. 2013). Taken 
together, our results and the recent literature support the hypothesis that 
EMT plays an important role in the biology of RCC. 
4.2 Prognostic significance of EMT genes in primary RCC tumors 
The EMT process induces enhanced cell invasion, dissemination of tumor 
cells and metastasis by a switch from an epithelial to a more sarcomatoid 
phenotype. Therefore, it is not unexpected that higher levels of EMT-
associated gene products have been found to represent markers for poor 
prognosis in a number of solid tumors (Iwatsuki, Mimori et al. 2010). This 
has also been noted in RCC patients for selected EMT-associated genes in 
this study and by other groups (Kallakury, Karikehalli et al. 2001, Cho, 
Shim et al. 2003, Bandiera, Melloni et al. 2009, Mikami, Katsube et al. 
2011, Harada, Miyake et al. 2012). We found significantly reduced tumor-
specific survival for higher mRNA expression of CXCR4, VIM, FN1 and 
TWIST (Figure 8). Earlier tumor progression or reduced tumor-specific 
survival was also reported for elevated expression levels of TWIST, VIM, 
FN1, MMP2 as well as for SNAI1 and SNAI2 protein levels as determined 
by immunohistology for patients with clear cell RCC (Yang, Sun et al. 
2010, Mikami, Katsube et al. 2011, Harada, Miyake et al. 2012, Steffens, 
Schrader et al. 2012). Some of these proteins are functionally linked to 
tumor progression like the transcription factors SNAI1, SNAI2 and 
TWIST which are key inducers of EMT genes. VIM and the 
metalloproteinase MMP2 are responsible for adhesion, migration and 
survival and degradation of the extracellular matrix as well as the basal 
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membrane, respectively, and therefore instrumental for invasive growth 
(Orlichenko and Radisky 2008, Yamasaki, Seki et al. 2012, De Craene and 
Berx 2013).  
In summary, EMT represents a process which facilitates the progression 
of tumors. The results of this study demonstrate that a higher expression 
of EMT markers indicates worse outcome in RCC patients. CXCR4 and 
VIM were independent prognostic factors for tumor-specific survival. This 
result might be useful for clinical outcome evaluation and precise risk 
stratification of RCC patients, a precondition for an individualized 
therapeutic strategy. 
4.3 Reduced expression of EMT genes and reversal cadherin 
switch indicates MET in RCC metastasis 
E-cadherin is an epithelial adhesin, down-regulated when EMT takes 
place, while N-cadherin functions as a mesenchymal adhesion molecule, 
which is supposed to be up-regulated during tumor progression (Araki, 
Shimura et al. 2011). This is consistent with the loss of polarity and the 
gain of migratory capacity associated with tumor progression. This E-
cadherin/N-cadherin switch was found to be an important signal for EMT 
and has been proven to be responsible for the progression of prostate 
cancer (Tomita, van Bokhoven et al. 2000, Gravdal, Halvorsen et al. 2007). 
The prognostic power of EMT gene expression to predict tumor-specific 
survival of RCC patients appears to be lost in metastases samples. This 
might be explained by the fact that metastasis rarely occurs from 
metastases (Klein 2009), and EMT gene expression does not necessarily 
enhance growth of metastases (Tsai, Donaher et al. 2012). Rather reversal 
of EMT i.e. mesenchymal-epithelial transition (MET) seems to be 
important for disseminated tumor cells for the establishment of macro-
metastases (Tsai, Donaher et al. 2012). Indeed, some EMT associated 
genes (ZEB1, CDH2, CXCR7) seem to be down-regulated in metastases 
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compared to primary tumors, most notably the CDH2/CDH1 expression 
ratio which is elevated in primary RCC is significantly smaller in 
metastases which would be indicative of MET to occur in RCC metastases. 
Through the dynamic regulation of EMT-related microRNAs or ZEB1/2 
(Kurahara, Takao et al. 2012, Yoshino, Enokida et al. 2013), E-cadherin to 
N-cadherin switch represents the manifestations of EMT, and MET is 
represented by the N-cadherin to E-cadherin switch accordingly. Two 
studies of RCC in colorectal cancer (Brabletz, Hlubek et al. 2005, 
Spaderna, Schmalhofer et al. 2007) showed that MET is detectable in 
metastasis of colorectal cancer which favors the differentiation of primary 
tumor cells to finally form metastasis in the colonized area. 
In RCC, no study to our knowledge has included samples from metastases 
for analyzing the expression of EMT genes. This is the first study on this 
topic and still much is unknown. Further investigations are needed to 
clarify the role of EMT and MET in RCC metastases, but the results of 
this study support the hypothesis that MET occurs in RCC metastases. 
4.4 G1 and G3 primary tumor share similar expression pattern of 
the EMT gene set 
No significant enrichment of the EMT gene transcripts has been found in 
G3 compared to G1 primary tumors (Figure 2). Hence, the less 
differentiated state in G3 tumors does not necessarily correspond to a shift 
towards an EMT gene expression pattern. However, in clear cell RCC with 
both carcinomatous and sarcomatous components, the E-cadherin to N-
cadherin switching as well as elevated expression of SNAIL and secreted 
protein acidic and rich in cysteine (SPARC), another typical EMT protein 
(Table 6), has been described to occur preferentially in the sarcomatoid 
tumor component (Conant, Peng et al. 2011). 
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4.5 CXCR4: a link between EMT and cancer stem cell properties in 
RCC 
The metastatic cascade appears to be highly inefficient and only a small 
proportion of cancer cells are responsible for cell seeding to metastatic 
sites. Recent studies suggest that this small subpopulation of carcinoma 
cells exhibit cancer stem cell properties thus linking cancer stem cells to 
metastasis (Sampieri and Fodde 2012). It has been proposed that 
carcinoma cells undergo a characteristic change from an epithelial to a 
mesenchymal cell-like phenotype during cancer progression (Tiwari, 
Gheldof et al. 2012). This process of epithelial-mesenchymal transition 
(EMT) involves reduction of cell-cell adhesion and acquisition of invasive 
properties. Cells undergoing EMT or gaining stem cell properties are 
sharing similar cell phenotype changes, and both lead to tumor 
progression and metastases formation.  
A link between the EMT phenotype and cancer stem cell properties has 
been suggested previously (Mani, Guo et al. 2008, Singh and Settleman 
2010). We have shown recently that CXCR4 represents a marker for 
cancer stem cells and is important for their maintenance in RCC cell lines 
(Gassenmaier, Chen et al. 2013). Besides RCC, CXCR4 is also recognized 
as stem cell marker in breast and prostate cancer (Dubrovska, Elliott et al. 
2012, Dubrovska, Hartung et al. 2012). In addition, CXCR4 signaling can 
induce EMT as shown for pancreatic cancer cells (Li, Ma et al. 2012). 
CXCR4 can be down-regulated by the von Hippel-Lindau tumor 
suppressor pVHL (Staller, Sulitkova et al. 2003, Struckmann, Mertz et al. 
2008) and higher expression of CXCR4 predicts poor prognosis in renal cell 
carcinoma (D'Alterio, Consales et al. 2010). This can be explained by the 
cancer stem cell properties mediated by high level of CXCR4 (Singh, Singh 
et al. 2004). Up-regulation of CXCR4 is also accompanied with epithelial-
mesenchymal transition and induces cell invasion in pancreatic cancer 
and oral squamous cell carcinoma (Onoue, Uchida et al. 2006, Taki, 
DISCUSSION 
56 
 
Higashikawa et al. 2008, Li, Ma et al. 2012). These findings suggest that 
CXCR4 might also be a link between EMT and cancer stem cells in RCC.  
In this study, it could be shown that CXCR4 has a significantly increased 
expression in RCC primary tumors and metastases at both the mRNA and 
protein level. Furthermore, CXCR4 expression was a significant 
prognostic marker for tumor-specific survival in univariate analysis as 
well as an independent prognostic marker in the multivariate Cox 
regression model. According to the previous finding that CXCR4-positive 
cells represent cancer stem cells in RCC, it can be concluded that higher 
CXCR4 expression is directly correlated with the tumor cell capability of 
cell renewal, migration, invasion and metastasis. 
Since cancer stem cells are often more resistant to drugs, CXCR4-targeted 
molecules could be used for the therapy of RCC. Such therapies could 
target the CXCR4 signaling pathway in combination with e.g. anti-
angiogenic therapies commonly used in patients with advanced disease 
(Gonzalez Larriba, Espinosa et al. 2012, Domanska, Kruizinga et al. 2013).  
4.6 No defined sub-population of CXCR4+/ TPBG+ cells were 
observed in RCC cell line 
TPBG shows increased expression and prognostic significance in 
malignant pleural mesothelioma (Al-Taei, Salimu et al. 2012),  leukemia 
(Castro, McGinn et al. 2012), cervical cancer (Jones, Roberts et al. 1990), 
gastric cancer (Naganuma, Kono et al. 2002), colorectal cancer 
(Starzynska, Marsh et al. 1994) and at high level in renal cell carcinoma 
(Elkord, Shablak et al. 2009). TPBG was used as a target for 
immunotherapy in renal cell carcinoma in a series of studies (Shaw, 
Connolly et al. 2007, Tykodi and Thompson 2008, Tykodi, Satoh et al. 
2012). Several therapies were developed to target TPBG, such as 
vaccination with modified vaccinia Ankara-5T4 (Tykodi and Thompson 
2008, Hawkins, Macdermott et al. 2009), anti-5T4 antibody (Sapra, 
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Damelin et al. 2013) and 5T4-based tumor-targeted super-antigens (Shaw, 
Connolly et al. 2007). Preclinical effects of these drugs were promising and 
complete clinical evaluation is still ongoing. 
It has been reported that E-cadherin stabilizes the cortical actin 
cytoskeletal arrangement and this prevents cell surface localization of the 
5T4 antigen. Interestingly, presentation of the TPBG antigen at the cell 
surface is accompanied by the mesenchymal phenotype during ES cell 
differentiation (Ward, Eastham et al. 2006, Eastham, Spencer et al. 2007, 
Spencer, Eastham et al. 2007). Upon surface localization, TPBG antigen 
disrupts cell-cell contacts and induces cellular motility in epithelial cells 
(Carsberg, Myers et al. 1996).  
TPBG is important for keeping CXCR4 on the cell surface and for CXCR4-
mediated signaling (Southgate, McGinn et al. 2010, McGinn, Marinov et al. 
2012), which is reported to be important for metastasis in lung tumors, 
breast cancers and renal cell carcinomas (Pan, Mestas et al. 2006, 
Hamatake, Aoki et al. 2009, D'Alterio, Barbieri et al. 2012, Hawkins and 
Richmond 2012). 
According to the finding that CXCR4 is maintained at the cell surface by 
TPBG which allows progression-related signaling, we assumed that TPBG 
and CXCR4 are probably co-expressed in certain “sub-populations” on the 
cell surface, which directly facilitates CXCR4 signaling. Targeting such 
“sub-population” cells could be promising to inhibit tumor invasion and 
metastasis. 
However, flow cytometry results in two RCC cell lines RCC53 and SK-RC-
17 did not support this assumption. No double-positive staining “sub-
population” was found in the selected cell lines. A possible explanation of 
this finding could be as follows: 
It might not be necessary for TPBG to be expressed on the cell surface to 
maintain the surface expression of CXCR4. It is found that the proportions 
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of TPBG and CXCR4 are different and are not correlated in different cell 
lines: in RCC53, 11% of cells are TPBG-positive and only 3.2% of cells are 
CXCR4-positive; in SK-RC-17, 0.3% of cells are TPBG-positive and around 
1.4% of cells are CXCR4-positive. The surface expressions of these two 
molecules are not correlated with each other. Since there appears to have 
a functional connection between them, it is assumed that during the 
maintanace of CXCR4 surface expression, all TPBG molecules are not 
necessary to be on the outer cell membrane, but might also be in 
intracellular compartments where it could interact with CXCR4. However, 
this assumption has to be proven by additional studies about the mode of 
interaction between the two molecules. In one study on small cell lung 
cancer cell line H1048, TPBG knockdown using shRNA did not affect the 
surface expression of CXCR4 (McGinn, Marinov et al. 2012), while the 
surface expression of TPBG obviously decreased. This result partially 
supports the finding in this study.  
4.7 High expression of ATAD2, TET3, HELLS and TOP2A are 
independent predictors of poor outcome in RCC patients 
Additionally to the focus on EMT- and cancer stem cell-related genes, a 
novel filtering strategy was used on oligonucleotide microarray data to 
identify potential new prognostic markers. Genes with increasing 
expression during tumor progression (expression in normal kidney < in 
primary tumor < in metastases) could be essential for a malignant 
phenotype and could therefore have influence on the patients’ outcome. 
Such genes were selected from the array data and analyzed by univariate 
analysis. The best candidate genes were then validated by RT-PCR. Using 
this strategy, ATAD2, TET3, HELLS and TOP2A could be identified as 
independent prognostic markers for tumor-specific survival of RCC 
patients. 
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ATAD2, as a tumor-promoting factor cooperating with a series of 
transcription factors including MYC (Ciro, Prosperini et al. 2009), is up-
regulated in many cancers and predicts poor prognosis in osteosarcoma, 
breast cancer and lung cancer (Fellenberg, Bernd et al. 2007, Caron, 
Lestrat et al. 2010). TET3, a member of the ten-eleven translocation (TET) 
gene family, is an epigenetic mediator which plays a role in DNA 
demethylation. HELLS, encoding a lymphoid-specific helicase, play an 
essential role in normal development and cell survival through DNA 
methylation (Myant and Stancheva 2008). HELLS was also identified as a 
cancer progression marker in head and neck squamous cell carcinoma 
(Waseem, Ali et al. 2010). TOP2A, which was examined in bladder cancer 
and breast cancer to be co-amplified with the HER2 oncogene (Bofin, 
Ytterhus et al. 2003, Simon, Atefy et al. 2003), is also a proliferation-
related and prognosis-predicting gene in breast cancer and colorectal 
cancer (Yang and Jia 2010, Zaczek, Markiewicz et al. 2012).  
Up to date, no publication combining any of these four genes with RCC 
was found. Further studies on these potential novel prognostic markers for 
RCC are needed to confirm their role in RCC biology. 
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5. Summary 
 
The clinical course of renal cell carcinoma (RCC) shows a high variability. 
Prognostic markers are essential to enable an individualized therapeutic 
strategy. The objective of this study was the identification of novel 
independent prognostic markers and potential therapeutic targets in RCC. 
The focus was on genes involved in epithelial-mesenchymal transition 
(EMT) and cancer stem cell biology.  
EMT enhances tumor cell motility and hence plays a critical role in 
invasion and metastasis in various carcinomas. A set of transcription 
factors acts as master regulators of EMT. Whether EMT is important for 
tumor progression in clear cell renal cell carcinoma (RCC) is unknown. 
Therefore, EMT-related genes were selected from the literature, and their 
role and prognostic relevance in RCC were analyzed. The known cancer 
stem cell marker CXCR4 and the associated TPBG gene were also 
analyzed in this project. Additionally, a novel filter strategy was used to 
analyze RCC oligonucleotide microarray data for identification of potential 
prognostic markers: genes with increasing expression during tumor 
progression (normal kidney < primary tumor < metastases) were selected 
for outcome analysis because they could be crucial for RCC biology. 
Expression of 46 EMT-related genes was analyzed using oligonucleotide 
microarrays and gene set enrichment analysis (GSEA) in tissue samples 
from normal kidney and G1 and G3 primary RCC, 14 samples each. 
Expression of selected EMT genes was validated by real-time polymerase 
chain reaction (PCR) in normal kidney, primary RCC and metastases in 
an independent cohort of 112 patients and then combined with follow-up 
data for survival analysis. Immunohistochemistry, Western blot and flow 
cytometry were performed to further examine the expression of CXCR4 
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and co-expression of CXCR4 and TPBG on the surface of RCC cells. GSEA 
and dChip software were used for microarray data analysis. 
The EMT gene set was preferentially expressed in primary tumors 
compared to normal tissue (false discovery rate FDR=0.01), but no 
difference between G1 and G3 tumors was found. Quantitative RT-PCR 
showed down-regulation of critical EMT genes like CDH2 and ZEB1 in 
metastases which suggests reversal of EMT during metastasis. Kaplan-
Meier analysis demonstrated a significant better outcome for patients 
with low CXCR4, vimentin, fibronectin and TWIST1 mRNA levels. 
Multivariate analysis revealed that CXCR4 and vimentin up-regulation 
represent independent prognostic markers for poor cancer-specific survival 
of RCC patients. The microarray approach using filtering and further RT-
PCR validation of progression-associated genes revealed that ATAD2, 
TET3, HELLS and TOP2A are independent and previously unknown 
predictors of poor outcome in RCC patients. 
Taken together, this study provides strong evidence that EMT occurs in 
RCC. Modulation of EMT in RCC, therefore, might represent a future 
therapeutic option. Expression levels of a number of EMT-related genes 
(like the genes encoding the cancer stem cell marker CXCR4 and vimentin) 
could be identified as independent prognostic markers. Using a novel 
filtering approach on array data, additional novel prognostic markers 
could be identified. These findings contribute to a better risk stratification 
of RCC patients that can support an individualized and optimized 
therapeutic strategy. 
ZUSAMMENFASSUNG 
62 
 
6. Zusammenfassung 
 
Der klinische Verlauf des Nierenzellkarzinoms (RCC) zeigt eine hohe 
Variabilität. Prognostische Marker sind unerlässlich, um eine individuelle 
Therapiestrategie zu ermöglichen. Das Ziel dieser Studie war die 
Identifizierung neuer unabhängiger prognostischer Marker und 
potentieller therapeutischer Targets beim RCC. Der Schwerpunkt lag auf 
Genen, die bei der Epithelial-Mesenchymalen Transition (EMT) und 
Tumorstammzellenbiologie beteiligt sind. 
EMT steigert die Beweglichkeit von Tumorzellen und spielt eine 
entscheidende Rolle bei der Invasion und Metastasierung bei 
verschiedenen Karzinomen. Eine Reihe von Transkriptionsfaktoren 
fungiert als die Hauptregulatoren von EMT. Ob EMT wichtig ist für die 
Tumorprogression beim klarzelligen Nierenzellkarzinom (RCC), ist 
unbekannt. Daher wurden EMT-Gene aus der Literatur ausgewählt und 
ihre Rolle und prognostische Relevanz bei RCC wurden analysiert. Der 
bekannte Tumorstammzellmarker CXCR4 und das damit assoziierte 
TPBG-Gen wurden auch in diesem Projekt analysiert. Zusätzlich wurde 
eine neuartige Filter-Strategie bei RCC-Microarray-Daten verwendet, um 
mögliche prognostische Marker zu identifizieren: Gene mit zunehmender 
Expression während der Tumorprogression (normale Niere < Primärtumor 
< Metastasen) wurden für die Outcome-Analyse ausgewählt, weil sie 
entscheidend für die RCC-Biologie sein könnten. 
Die Expression von 46 EMT-Genen wurde mit Oligonukleotid-Microarrays 
und Gene Set Enrichment Analysis (GSEA) an Gewebeproben von 
normaler Niere und G1 und G3 Primärtumoren (jeweils 14 Proben) 
analysiert. Die Expression von ausgewählten EMT-Genen wurde mittels 
RT-PCR in normaler Niere, primärem RCC und Metastasen an einer 
unabhängigen Kohorte von 112 Patienten validiert und dann mit Follow-
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up-Daten für die Survivalanalyse kombiniert. Immunhistochemie, 
Western Blot und Durchflusszytometrie wurden durchgeführt, um die 
Expression von CXCR4 und die Co-Expression von CXCR4 und TPBG auf 
der Oberfläche von RCC-Zellen weiter zu untersuchen. Die Software 
GSEA und dChip wurde für die Analyse der Microarray-Daten verwendet. 
Das EMT-gene set wurde bevorzugt in Primärtumoren exprimiert, 
verglichen mit dem Normalgewebe (false discovery rate FDR = 0,01), es 
wurde aber kein Unterschied zwischen G1- und G3-Tumoren gefunden. 
Quantitative RT-PCR zeigte Herunterregulation von kritischen EMT-
Genen wie CDH2 und ZEB1 in Metastasen, was eine Umkehrung der 
EMT während der Metastasierung vermuten lässt. Die Kaplan-Meier-
Analyse zeigte signifikant bessere Ergebnisse für die Patienten mit 
niedriger CXCR4, Vimentin, Fibronectin und TWIST1 mRNA Expression. 
Die multivariate Analyse zeigte, dass eine Hochregulierung von CXCR4 
und Vimentin unabhängige prognostischer Marker darstellen für ein 
schlechtes tumorspezifisches Überleben von RCC-Patienten. Der 
Microarray-Ansatz mit Filtern und weiterer RT-PCR-Validierung der 
Progressions-assoziierten Gene ergab, dass ATAD2, TET3, HELLS und 
TOP2A unabhängige und bisher unbekannte Prädiktoren für schlechtes 
Outcome bei RCC-Patienten sind. 
Insgesamt liefert diese Studie deutliche Hinweise, dass EMT bei RCC 
vorkommt. Die Modulation von EMT bei RCC könnte daher eine 
zukünftige therapeutische Option darstellen. Die Expressionsstärke 
einiger EMT-Gene (z.B. die Gene für den Tumorstammzellmarker CXCR4 
und Vimentin) konnten als unabhängige prognostische Marker 
identifiziert werden. Mit Hilfe eines neuartigen Filter-Ansatzes bei Array-
Daten konnten zusätzliche neue prognostische Marker identifiziert 
werden. Diese Ergebnisse tragen bei zu einer besseren 
Risikostratifizierung von RCC-Patienten, was eine individualisierte und 
optimierte Therapiestrategie unterstützen kann. 
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8. Abbreviations 
 
7-AAD 7-aminoactinomycin D 
ß-ME beta-mercaptoethanol 
CMV human cytomegalus virus  
CSC cancer stem cell 
D days 
DMEM Dulbecco’s modiﬁed Eagle’s media 
DNA deoxyribonucleic acid 
dNTP Deoxynucleotide_triphosphate 
E. coli Escherichia coli 
EMT epithelial-mesenchymal transition 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FGF fibroblast growth factor 
FITC fluorescein isothiocyanate 
GAPDH glyceraldehyde-3-phosphate-dehydrogenase 
H hour 
HRP horseradish-peroxidase 
IgG immunoglobin G 
IHC immunohistochemistry 
Kb kilobases 
kD kilo Dalton 
LB lysogeny broth 
M mole 
MET mesenchymal-epithelial transition 
Mg milligram 
Min minute 
Ml milliliter 
mM millimolar 
mRCC metastatic renal cell carcinoma 
mRNA messenger ribonucleic acid 
µg microgram 
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µl microliter 
nm nanometer 
PBS phosphate-buﬀered saline 
PCR polymerase chain reaction 
qPCR quantitative polymerase chain reaction 
RCC renal cell carcinoma 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RT-PCR real-time reverse transcription PCR 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TBS/T Tris-buﬀered saline supplemented with Tween-20 
TPBG trophoblast glycoprotein 
Tris 2-amino-2-hydroxymethyl-propane-1,3-diol 
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